ClinicalTrials.gg
CompletedNCT03329092REVISITUpdated Dec 10, 2024Results posted

A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.

A Phase 3 interventional study of ATM-AVI and MTZ in Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia and Ventilator Associated Pneumonia, sponsored by Pfizer. Completed at 157 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-10.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
422
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Pneumonia, Ventilator-Associated with a site in China — 10 open to participants now, 11 under way, none of them phase 3. Pneumonia, Ventilator-Associated · China.

Enrollment
5th of 17
422 · median 174
Started
2018
with 1 other
Phase 3
3 of 26
none open now
Registered
7th of 26
by date
Lead sponsor
4 of 26
Pfizer

Among the 26 studies in Pneumonia, Ventilator-Associated with a site in China, this one is the 5th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2018, is one of 3 in phase 3, and was the 7th registered.

Pneumonia, Ventilator-Associated

420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.

Browse Pneumonia, Ventilator-Associated studies →

Open to participants now

10 of the 26 studies in Pneumonia, Ventilator-Associated with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Pneumonia, Ventilator-Associated with a site in China, or all of them as a file.
02

Study summary

A Phase 3 comparative study to determine the efficacy, safety and tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) versus Meropenem (MER) ± Colistin (COL) for the treatment of serious infections due to Gram negative bacteria.

Read the detailed description

A Phase 3 Prospective, Randomized, Multicenter, Open Label, Central Assessor Blinded, Parallel Group, Comparative Study To Determine The Efficacy, Safety And Tolerability Of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem±Colistin (MER±COL) For The Treatment Of Serious Infections Due To Gram Negative Bacteria, Including Metallo Β Lactamase (MBL) - Producing Multidrug Resistant Pathogens, For Which There Are Limited Or No Treatment Options

03

Conditions studied

  • Complicated Intra-abdominal Infection
  • Hosptial Acquired Pneumonia
  • Ventilator Associated Pneumonia

Keywords

  • Complicated intra-abdominal infection
  • Hosptial acquired pneumonia
  • Ventilator associated pneumonia
  • Gram negative infections
  • Metallo-beta lactamase
  • Multi drug resistant pathogens
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All subjects:

  1. Male or female from 18 years of age
  2. Provision of
  3. Confirmed diagnosis of HAP/VAP or cIAI requiring iv antibiotic treatment
  4. Female patients are authorized to participate in this clinical study if criteria concerning pregnancy avoidance stated in the protocol are met and negative pregnancy test

Additional for cIAI:

  1. Diagnosis of cIAI, EITHER:

    Intra-operative/postoperative enrolment with visual confirmation of cIAI. OR Preoperative enrollment with evidence of systemic inflammatory response, physical and radiological findings consistent with cIAI; confirmation of cIAI at time of surgery within 24 hours of study entry

  2. Surgical intervention within 24 hours (before or after) the administration of the first dose of study drug

Additional for HAP/VAP:

  1. Onset symptoms > 48h after admission to or \<7 days after discharge from an inpatient care facility
  2. New or worsening infiltrate on CXR or CT scan
  3. Clinical signs and symptoms and laboratory findings consistent with HAP/VAP
  4. Respiratory specimen obtained for Gram stain and culture following onset of symptoms and prior to randomisation

Exclusion criteria

Exclusion criteria:

All subjects:

  1. APACHE II score > 30
  2. Confirmed or suspected infection caused by Gram-negative species not expected to respond to study drug, or Gram-positive species
  3. Receipt of >24 hr systemic antibiotic within 48h prior to randomisation (exception in case of treatment failure)
  4. History of serious allergy, (eg, anaphylaxis), or any serious reaction to aztreonam, carbapenem,monobactam or other β-lactam antibiotics, avibactam, nitroimidazoles or metronidazole, or any of the of the study drugs
  5. Known Clostridium difficle associated diarrhoea
  6. Requirement for effective concomitant systemic antibacterials or antifungals
  7. ≤15 ml/min or requirement or expectation for renal replacement therapy
  8. Acute hepatitis, cirrhosis, acute hepatic failure, chronic hepatic failure
  9. Hepatic disease as indicated by or ALT >3 × . Patients with AST and/or ALT up to 5 × ULN are eligible if acute and documented by the investigator as being directly related infectious process
  10. Patient has a total >2 × ULN, unless isolated hyperbilirubinemia is directly related to infectious process or due to known Gilbert's disease
  11. ALP >3 × ULN. Patients with values >3 × ULN and \<5 x ULN are eligible if acute and directly related to the infectious process being treated
  12. \<500/mm3
  13. Pregnant or breastfeeding or if of child bearing potential, not using a medically accepted effective method of .
  14. Any other condition that may confound the results of the study or pose additional risks to the subject
  15. Unlikely to comply with protocol
  16. History of epilepsy or seizure disorders excluding febrile seizures of childhood

Additional for cIAI

  1. Diagnosis of abdominal wall abscess; small bowel obstruction or ischemic bowel disease without perforation; traumatic bowel perforation with surgery within 12 hours of diagnosis; perforation of gastroduodenal ulcer with surgery \< 24 hours of diagnosis primary etiology is not likely to be infectious
  2. Simple cholecystitis, gangrenous cholecystitis without rupture, simple appendicitis, acute suppurative cholangitis, infected necrotizing pancreatitis, pancreatic abscess
  3. Prior liver, pancreas or small-bowel transplant
  4. Staged abdominal repair (STAR), open abdomen technique or marsupialisation

Additional for HAP/VAP

  1. APACHE II score \< 10
  2. Known or high likelihood of Gram-positive monomicrobial infection
  3. Lung abscess, pleural empyema, post-obstructive pneumonia
  4. Lung or heart transplant
  5. Myasthenia gravis
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
422 participants (actual)

Study arms

  • Experimental
    Aztreonam-Avibactam ± Metronidazole

    All patients randomised to this arm will receive ATM-AVI; all patients with cIAI will receive MTZ for anaerobic cover

    Drug: ATM-AVI · Drug: MTZ

  • Active comparator
    Meropenem ± Colistin

    All patients randomised to this arm will receive MER; addition of COL will be at investigator's discretion in line with local practice

    Drug: MER · Drug: COL

Interventions

  • DrugATM-AVI

    (Creatinine clearance \> 50 mL/min) 6500 mg ATM/2167 mg (loading dose, extended loading dose and maintenance dose) by iv infusion on Day 1 followed by a total daily dose of 6000 mg ATM/2000 mg AVI (Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1417 mg AVI on Day 1 (loading dose, extended loading dose, maintenance dose) followed by total daily dose 3000 mg ATM/1000 mg AVI (Creatinine clearance 16 - 30 mL/min) 2700 mg ATM/900 mg AVI on Day 1 (loading dose, extended loading dose maintenance dose), followed by total daily dose 2025 mg ATM/675 mg AVI

  • DrugMTZ

    For cIAI only; 500 mg/100 mL metronidazole iv infusion over 1hr q8h

  • DrugMER

    Where pathogen initially not suspected of being MER-resistant: (Creatinine clearance \> 50 mL/min) 1000 mg meropenem by 30 min iv infusion q8h (Creatinine clearance 26 - 50 mL/min) 1000mg meropenem by 30 min iv infusion q12h (Creatinine clearance 16 - 25 mL/min) 500 mg meropenem by 30 min iv infusion q12h Where pathogen initially suspected of being MER-resistant (Creatinine clearance \> 50 mL/min) 2000 mg meropenem by 180 min iv infusion q8h (Creatinine clearance 26 - 50 mL/min) 2000 mg meropenem by 180 min iv infusion q12h (Creatinine clearance 16 - 25 mL/min) 1000 mg meropenem by 180 min iv infusion q12h

  • DrugCOL

    Loading dose 9 million IU by 30 -60 min iv infusion (6 million IU where weight \< 60 kg) followed by one of the following maintenance doses: (Creatinine clearance \> 50 mL/min) after a 12h interval, commence maintenance dosing 9 million IU daily in 2 or 3 divided doses by 30 -60 min iv infusions. (Creatinine clearance 31 - 50 mL/min) After a 24 hr interval, commence maintenance dosing of 6 million IU daily in 2 divided doses by 30 -60 min iv infusion (Creatinine clearance 21 - 30 mL/min) After a 24 hr interval, commence maintenance dosing 5 million IU daily in 2 divided doses by 30 -60 min iv infusion (Creatinine clearance 16 - 20 mL/min) after a 24 hr interval, commence maintenance dosing 4 million IU daily in 2 divided doses by 30 -60 min iv infusion

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Clinical Cure at Test of Cure (TOC) Visit: Intent-To-Treat (ITT) Analysis Set

    Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% confidence interval (CI) was based on Jeffrey's method.

    Time frame: At TOC visit (Day 28)

  2. Percentage of Participants With Clinical Cure at TOC Visit: Clinically Evaluable (CE) Analysis Set

    Clinical cure = improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method. CE analysis set:all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.

    Time frame: At TOC visit (Day 28)

Secondary outcomes

  1. Percentage of Participants With Clinical Cure at TOC Visit: Microbiological Intent-To-Treat (Micro-ITT) Analysis Set

    Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.

    Time frame: At TOC visit (Day 28)

  2. Percentage of Participants With Clinical Cure at TOC Visit: Microbiologically Evaluable (ME) Analysis Set

    Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.

    Time frame: At TOC visit (Day 28)

  3. Percentage of Participants With Clinical Cure at TOC Visit by Type of Infection: ITT Analysis Set

    Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.

    Time frame: At TOC visit (Day 28)

  4. Percentage of Participants With Clinical Cure at TOC Visit by Type of Infection: CE Analysis Set

    Clinical cure = improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method. CE analysis set:all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.

    Time frame: At TOC visit (Day 28)

  5. Percentage of Participants With Clinical Cure in Participants With Metallo-beta-lactamase (MBL) Positive Pathogen at TOC Visit: Micro-ITT Analysis Set

    Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee.

    Time frame: At TOC visit (Day 28)

  6. Percentage of Participants With Clinical Cure in Participants With MBL Positive Pathogen at TOC Visit: ME Analysis Set

    Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee.

    Time frame: At TOC visit (Day 28)

  7. Percentage of Participants With Favorable Per-Participant Microbiological Response at TOC Visit: Micro- ITT Analysis Set

    Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure.

    Time frame: At TOC visit day (28)

  8. Percentage of Participants With Favorable Per-Participant Microbiological Response at TOC Visit: ME Analysis Set

    Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure.

    Time frame: At TOC Visit (Day 28)

  9. Percentage of Participants Who Died on or Before 28 Days After Randomization: ITT Analysis Set

    Percentage of participants who died on or before 28 days after randomization is reported in this outcome measure.

    Time frame: From randomization up to 28 days

  10. Percentage of Participants Who Died on or Before 28 Days After Randomization: Micro-ITT Analysis Set

    Percentage of participants who died on or before 28 days after randomization is reported in this outcome measure.

    Time frame: From randomization up to 28 days

  11. Plasma Concentration of Aztreonam

    Plasma concentration for aztreonam according to renal function (augmented, normal and mild, moderate and severe is presented in this outcome measure. Augmented = Creatinine clearance (CrCL) \> 150 milliliters per minute (mL/min); Normal \& Mild = CrCL \> 50 to \<=150 mL/min; Moderate = CrCL \> 30 to ≤ 50 mL/min; Severe = CrCL \> 15 to ≤ 30 mL/min.

    Time frame: Anytime between 25 to 30 minutes, 3.25 to 3.5 hours, 5.5 to 6.5 hours, 7.5 to 8.5 hours post start of infusion on Day 1; 2.75 to 3 hours, 3.5 to 4.5 hours, 5 to 6 and 7 to 8 hours post start of infusion on Day 4

  12. Plasma Concentration of Avibactam

    Plasma concentration for avibactam according to renal function (augmented, normal and mild, moderate and severe is presented in this outcome measure. Augmented = CrCL \> 150 mL/min; Normal \& Mild = CrCL \> 50 to \<=150 mL/min; Moderate = CrCL \> 30 to ≤ 50 mL/min; Severe = CrCL \> 15 to ≤ 30 mL/min.

    Time frame: Anytime between 25 to 30 minutes, 3.25 to 3.5 hours, 5.5 to 6.5 hours, 7.5 to 8.5 hours post start of infusion on Day 1; 2.75 to 3 hours, 3.5 to 4.5 hours, 5 to 6 and 7 to 8 hours post start of infusion on Day 4

  13. Maximum Plasma Concentration for a Dosing Interval at Steady-State (Cmax, ss) According to Clinical Response by Infection Type at TOC: Aztreonam

    Population PK predicted maximum plasma concentration for a dosing interval at steady-state (Cmax,ss) for participants who received aztreonam-avibactam in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Clinical response categories included, clinical cure=improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Failure was defined as participants who met any of the following criteria like death (after receiving at least 48 hours of study treatment) and participants who received treatment with further antibiotics for the index infection. Indeterminate was defined as death (after receiving less than 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.

    Time frame: At TOC (Day 28)

  14. Percentage of Time That Free Plasma Concentrations Are Above the Minimum Inhibitory Concentration Over a Dosing Interval (%fT>MIC Aztreonam (ATM) of 8 mg/L) According to Clinical Response by Infection Type at TOC: Aztreonam

    Population PK predicted (%fT\>MIC ATM of 8 mg/L) for participants who received aztreonam-avibactam in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Clinical response categories included, clinical cure=improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Failure was defined as participants who met any of the following criteria like death (after receiving at least 48 hours of study treatment) and participants who received treatment with further antibiotics for the index infection. Indeterminate was defined as death (after receiving less than 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.

    Time frame: At TOC (Day 28)

  15. Area Under the Plasma Concentration-time Curve Over 24 Hours at Steady-state (AUC24,ss ) According to Clinical Response by Infection Type at TOC: Aztreonam

    Population PK predicted (AUC24,ss) for participants who received aztreonam-avibactam in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Clinical response categories included, clinical cure=improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Failure was defined as participants who met any of the following criteria like death (after receiving at least 48 hours of study treatment) and participants who received treatment with further antibiotics for the index infection. Indeterminate was defined as death (after receiving less than 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.

    Time frame: 0 to 24 hours at TOC (Day 28)

  16. Maximum Plasma Concentration for a Dosing Interval at Steady-state (Cmax,ss) According to Microbiological Response by Infection Type at TOC: Aztreonam

    Population PK predicted (Cmax,ss) for participants who received ATM-AVI in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Microbiological response included Favorable =baseline pathogens for participant had a favorable outcome. Eradication: Absence of causative pathogen from an appropriately obtained specimen at site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Unfavorable=persistence, persistence with increasing MIC, or presumed persistence. Persistence= Causative organism still present from appropriately obtained specimen at site of infection. Presumed persistence= Participant assessed as a clinical failure and repeat culture of specimens were not performed/clinically indicated. Indeterminate = death (after receiving \< 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.

    Time frame: At TOC (Day 28)

  17. Area Under the Plasma Concentration-time Curve Over 24 Hours at Steady-state (AUC24,ss) According to Microbiological Response by Infection Type at TOC: Aztreonam

    Population PK predicted (AUC24,ss) for participants who received ATM-AVI in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Microbiological response included Favorable =baseline pathogens for participant had a favorable outcome. Eradication: Absence of causative pathogen from an appropriately obtained specimen at site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Unfavorable=persistence, persistence with increasing MIC, or presumed persistence. Persistence= Causative organism still present from appropriately obtained specimen at site of infection. Presumed persistence= Participant assessed as a clinical failure and repeat culture of specimens were not performed/clinically indicated. Indeterminate = death (after receiving \< 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.

    Time frame: 0 to 24 hours at TOC (Day 28)

  18. Percentage of Time That Free Plasma Concentrations Are Above the Minimum Inhibitory Concentration Over a Dosing Interval (%fT>MIC Aztreonam (ATM) of 8 mg/L) According to Microbiological Response by Infection Type at TOC: Aztreonam

    Population PK predicted (%fT\>MIC ATM of 8 mg/L) for participants who received ATM-AVI in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Microbiological response included Favorable =baseline pathogens for participant had a favorable outcome. Eradication: Absence of causative pathogen from an appropriately obtained specimen at site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Unfavorable=persistence, persistence with increasing MIC, or presumed persistence. Persistence= Causative organism still present from appropriately obtained specimen at site of infection. Presumed persistence= Participant assessed as a clinical failure and repeat culture of specimens were not performed/clinically indicated. Indeterminate = death (after receiving \< 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.

    Time frame: At TOC (Day 28)

  19. Area Under the Plasma Concentration-time Curve Over 24 Hours at Steady-state (AUC24,ss) According to Clinical Response by Infection Type at TOC: Avibactam

    Population PK predicted (AUC24,ss) for participants who received aztreonam-avibactam in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Clinical response categories included, clinical cure=improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Failure was defined as participants who met any of the following criteria like death (after receiving at least 48 hours of study treatment) and participants who received treatment with further antibiotics for the index infection. Indeterminate was defined as death (after receiving less than 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.

    Time frame: 0 to 24 hours at TOC (Day 28)

  20. Maximum Plasma Concentration for a Dosing Interval at Steady-state (Cmax,ss ) According to Clinical Response by Infection Type at TOC: Avibactam

    Population PK predicted (Cmax,ss) for participants who received aztreonam-avibactam in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Clinical response categories included, clinical cure=improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Failure was defined as participants who met any of the following criteria like death (after receiving at least 48 hours of study treatment) and participants who received treatment with further antibiotics for the index infection. Indeterminate was defined as death (after receiving less than 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.

    Time frame: At TOC (Day 28)

  21. Percent of Time That Free Plasma Concentrations Are Above the Threshold Concentration Over a Dosing Interval (%fT>CT of 2.5mg/L) According to Clinical Response by Infection Type at TOC: Avibactam

    Population PK predicted (%fT\>CT of 2.5mg/L) for participants who received aztreonam-avibactam in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Clinical response categories included, clinical cure=improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Failure was defined as participants who met any of the following criteria like death (after receiving at least 48 hours of study treatment) and participants who received treatment with further antibiotics for the index infection. Indeterminate was defined as death (after receiving less than 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.

    Time frame: At TOC (Day 28)

  22. Area Under the Plasma Concentration-time Curve Over 24 Hours at Steady-state (AUC24,ss) According to Microbiological Response by Infection Type at TOC: Avibactam

    Population PK predicted (AUC24,ss) for participants who received ATM-AVI in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Microbiological response included Favorable =baseline pathogens for participant had a favorable outcome. Eradication: Absence of causative pathogen from an appropriately obtained specimen at site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Unfavorable=persistence, persistence with increasing MIC, or presumed persistence. Persistence= Causative organism still present from appropriately obtained specimen at site of infection. Presumed persistence= Participant assessed as a clinical failure and repeat culture of specimens were not performed/clinically indicated. Indeterminate = death (after receiving\<48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.

    Time frame: 0 to 24 hours At TOC (Day 28)

  23. Maximum Plasma Concentration for a Dosing Interval at Steady-state (Cmax,ss (mg/L)) According to Microbiological Response by Infection Type at TOC: Avibactam

    Population PK predicted (Cmax,ss (mg/L)) for participants who received ATM-AVI in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Microbiological response included Favorable =baseline pathogens for participant had a favorable outcome. Eradication: Absence of causative pathogen from an appropriately obtained specimen at site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Unfavorable=persistence, persistence with increasing MIC, or presumed persistence. Persistence= Causative organism still present from appropriately obtained specimen at site of infection. Presumed persistence= Participant assessed as a clinical failure and repeat culture of specimens were not performed/clinically indicated. Indeterminate = death (after receiving\<48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.

    Time frame: At TOC (Day 28)

  24. Percent of Time That Free Plasma Concentrations Are Above the Threshold Concentration Over a Dosing Interval; (%fT>CT of 2.5 mg/L) According to Microbiological Response by Infection Type at TOC: Avibactam

    Population PK predicted (%fT\>CT of 2.5 mg/L) for participants who received ATM-AVI in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Microbiological response included Favorable =baseline pathogens for participant had a favorable outcome. Eradication: Absence of causative pathogen from an appropriately obtained specimen at site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Unfavorable=persistence, persistence with increasing MIC, or presumed persistence. Persistence= Causative organism still present from appropriately obtained specimen at site of infection. Presumed persistence= Participant assessed as a clinical failure and repeat culture of specimens were not performed/clinically indicated. Indeterminate = death (after receiving \< 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.

    Time frame: At TOC (Day 28)

  25. Number of Participants With Adverse Events (AEs) and Serious AEs

    An adverse event (AE) was any untoward medical occurrence in a study participant administered medicinal product,; the event need not necessarily have a causal relationship with product treatment or usage. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital abnormal/birth defect or considered an important medical event.

    Time frame: From start of study treatment until end of late follow-up (Up to Day 45)

  26. Number of Participants With Potentially Clinically Significant Hematology Abnormalities

    Criteria for potential clinically significant hematology results were as follows: hemoglobin, hematocrit and erythrocyte \<0.7\*lower limit of normal \[LLN\] and \>30% decrease from Baseline (DFB); \>1.3\*upper limit of normal (ULN) and \>30% increase from Baseline (IFB). Platelet count \<0.65\*LLN and \> 50% decrease from baseline; \> 1.5 \* ULN and \> 100% increase from baseline. leukocyte: \< 0.65\* LLN and \> 60% decrease from baseline; \> 1.5\* ULN and 100% increase from baseline. Neutrophils/leukocytes \< 0.65 \* LLN and \>75% decrease from baseline; \> 1.6\*ULN and \> 100% increase from baseline. Lymphocytes/leukocytes \< 0.25\* LLN and \> 75% decrease from baseline;\> 1.5\* ULN and \> 100% increase from baseline, Eosinophils/leukocytes, Monocytes/leukocytes, Basophils/leukocytes \> 4.0\* ULN and \> 300% increase from baseline.

    Time frame: From start of study treatment until TOC visit (Up to Day 28)

  27. Number of Participants With Potentially Clinically Significant Clinical Chemistry Abnormalities

    Albumin \< 0.5\* LLN and\> 50% decrease from baseline (DFB);\> 1.5 \* ULN and\> 50% increase from baseline (IFB). Alkaline phosphatase \< 0.5 \* LLN and\> 80% DFB;\> 3.0 \* ULN and\> 100%. Alanine and Aspartate aminotransferase \> 3.0 \* ULN and\> 100% IFB. Bicarbonate \< 0.7 \* LLN and \> 40% DFB;\> 1.3 \* ULN and\> 40% IFB. Blood urea nitrogen \< 0.2 \* LLN and \> 100% DFB; \> 3.0 \* ULN and \> 200% IFB. Calcium \< 0.7 \* LLN and \> 30% DFB;\> 1.3 \* ULN and\> 30% IFB. Chloride \< 0.8 \* LLN \>and 20% DFB; \> 1.2 \* ULN and \> 20% IFB. Creatinine \> 2.0 \* ULN and\> 100% IFB; Glucose \< 0.6 \* LLN and\> 40% DFB; \> 3.0 \* ULN and\> 200% IFB. Potassium \< 0.8 \* LLN and \> 20% DFB; \> 1.2 \* ULN and\> 20% IFB. Sodium \< 0.85 \* LLN and\> 10% DFB;\> 1.1 \* ULN and \>10% IFB. Bilirubin \> 1.5 \* ULN and \> 100% IFB.; Direct bilirubin \> 2.0 \* ULN and \> 150% IFB.

    Time frame: From start of study treatment until At TOC visit (Up to Day 28)

  28. Number of Participants With Abnormalities in Vital Signs

    Vitals signs, included blood pressure and, heart rate. Blood pressure (BP) and heart rate were measured using a semiautomatic BP recording device with the participant in a supine position after at least 10 minutes of rest. Criteria for abnormalities included: Systolic BP (millimeters of mercury \[mmHg\]): value more than (\>) 150 and increase from baseline more than equal (\>= 30) or value less than (\<) 90 and decrease from baseline \>= 30; DBP: value \> 100 and increase from baseline \>=20 or Value \< 50 and decrease from baseline \>= 20; Heart Rate (beats per minute \[BPM\]): value \< 40 or \> 120.

    Time frame: From start of study treatment until TOC visit (Up to Day 28)

  29. Number of Participants With Abnormal Physical Examination Finding

    A complete physical examination was performed and included an assessment of the following: general appearance including site of infection, skin, head and throat (head, eyes, ears, nose, and throat), lymph nodes, lungs, cardiovascular (CV), abdomen, musculoskeletal, and neurological systems.

    Time frame: Screening, End of treatment (up to 24 hours post infusion on Day 14) and Test of Cure (Day 28)

  30. Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings

    Standard 12-lead ECGs were recorded with the participants in the supine position after the participant had rested in this position for 10 minutes. Clinically significant findings were based on investigators assessment.

    Time frame: Baseline (latest non-missing value before start of treatment) and Day 3

Other outcomes

  1. Percentage of Participants With Clinical Cure at End of Treatment (EOT) Visit: ITT Analysis Set

    Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.

    Time frame: At EOT visit (Within 24 hours after last infusion on Day 14)

  2. Percentage of Participants With Clinical Cure at EOT Visit: Micro-ITT Analysis Set

    Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.

    Time frame: At EOT visit (Within 24 hours after last infusion on Day 14)

  3. Percentage of Participants With Clinical Cure at EOT Visit: CE Analysis Set

    Clinical cure = improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.

    Time frame: At EOT visit (Within 24 hours after last infusion on Day 14)

  4. Percentage of Participants With Clinical Cure at EOT Visit: ME Analysis Set

    Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.

    Time frame: At EOT visit (Within 24 hours after last infusion on Day 14)

  5. Percentage of Participants With Clinical Cure by Type of Infection at EOT Visit: ITT Analysis Set

    Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.

    Time frame: At EOT visit (Within 24 hours after last infusion on Day 14)

  6. Percentage of Participants With Clinical Cure by Type of Infection at EOT Visit: CE Analysis Set

    Clinical cure = improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.

    Time frame: At EOT visit (Within 24 hours after last infusion on Day 24)

  7. Percentage of Participants With Clinical Cure by Pathogen Resistance Type at EOT Visit: Micro-ITT Analysis Set

    Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. Percentage of participants with clinical cure by pathogen resistance type (ATM non-susceptible and Meropenem non-susceptible based on European Committee on Antimicrobial Susceptibility Testing \[EUCAST\] criteria and Clinical and Laboratory Standards Institute \[CLSI\] criteria, Extended spectrum beta-lactamases \[ESBL\]-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.

    Time frame: At EOT visit (Within 24 hours after last infusion on Day 14)

  8. Percentage of Participants With Clinical Cure by Pathogen Resistance Type at TOC Visit: Micro-ITT Analysis Set

    Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. Percentage of participants with clinical cure by pathogen resistance type (ATM non-susceptible and Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.

    Time frame: At TOC (Day 28)

  9. Percentage of Participants With Clinical Cure by Pathogen Resistance Type at EOT Visit: ME Analysis Set

    Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. Percentage of participants with clinical cure by pathogen resistance type (ATM non-susceptible and Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.

    Time frame: At EOT (Within 24 hours after last infusion on Day 14)

  10. Percentage of Participants With Clinical Cure by Pathogen Resistance Type at TOC Visit: ME Analysis Set

    Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. Percentage of participants with clinical cure by pathogen resistance type (ATM non-susceptible and Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.

    Time frame: At TOC visit (Day 28)

  11. Percentage of Participants With Favorable Per Participant Microbiological Response at EOT Visit: Micro-ITT Analysis Set

    Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure.

    Time frame: At EOT visit (Within 24 hours after last infusion on Day 14)

  12. Percentage of Participants With Favorable Per Participant Microbiological Response at EOT Visit : ME Analysis Set

    Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure.

    Time frame: At EOT visit (Within 24 hours after last infusion on Day 14)

  13. Number of Participants With Favorable Microbiological Response Per-Pathogen at EOT Visit: Micro-ITT Analysis Set

    Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Only those pathogens are reported which had more than or equal to 10 isolates for either treatment group.

    Time frame: At EOT (Within 24 hours after last infusion on Day 14)

  14. Number of Participants With Favorable Microbiological Response Per-Pathogen at at TOC Visit: Micro-ITT Analysis Set

    Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Only those pathogens are reported which had more than or equal to 10 isolates for either treatment group.

    Time frame: At TOC visit (Day 28)

  15. Number of Participants With Favorable Microbiological Response Per-Pathogen at EOT Visit: ME Analysis Set

    Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Only those pathogens are reported which had more than or equal to 10 isolates for either treatment group.

    Time frame: At EOT (Within 24 hours after last infusion on Day 14)

  16. Number of Participants With Favorable Microbiological Response Per-Pathogen at TOC Visit: ME Analysis Set

    Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Only those pathogens are reported which had more than or equal to 10 isolates for either treatment group.

    Time frame: At TOC visit (Day 28)

  17. Percentage of Participants With Favorable Per-Participant Microbiological Response by Pathogen Resistance Type at EOT Visit: Micro-ITT Analysis Set

    Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable microbiological response by pathogen resistance type (ATM non-susceptible and Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.

    Time frame: At EOT (Within 24 hours after last infusion on Day 14)

  18. Percentage of Participants With Favorable Per-Participant Microbiological Response by Pathogen Resistance Type at TOC Visit: Micro-ITT Analysis Set

    Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable microbiological response by pathogen resistance type (ATM non-susceptible and Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.

    Time frame: At TOC visit (Day 28)

  19. Percentage of Participants With Favorable Per-Participant Microbiological Response by Pathogen Resistance Type at EOT Visit: ME Analysis Set

    Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable microbiological response by pathogen resistance type (ATM non-susceptible, Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.

    Time frame: At EOT (Within 24 hours after last infusion on Day 14)

  20. Percentage of Participants With Favorable Per-Participant Microbiological Response by Pathogen Resistance Type at TOC Visit: ME Analysis Set

    Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable microbiological response by pathogen resistance type (ATM non-susceptible, Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.

    Time frame: At TOC visit (Day 28)

  21. Percentage of Participants With Favorable Per-Pathogen Microbiological Response by Pathogen Resistance Type at EOT Visit: Micro-ITT Analysis Set

    Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable per-pathogen microbiological response by pathogen resistance type (ATM non-susceptible, Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.

    Time frame: At EOT (Within 24 hours after last infusion on Day 14)

  22. Percentage of Participants With Favorable Per-Pathogen Microbiological Response by Pathogen Resistance Type at TOC Visit: Micro-ITT Analysis Set

    Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable per-pathogen microbiological response by pathogen resistance type (ATM non-susceptible, Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.

    Time frame: At TOC visit (Day 28)

  23. Percentage of Participants With Favorable Per-Pathogen Microbiological Response by Pathogen Resistance Type at EOT Visit: ME Analysis Set

    Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable per-pathogen microbiological response by pathogen resistance type (ATM non-susceptible, Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.

    Time frame: At EOT (Within 24 hours after last infusion on Day 14)

  24. Percentage of Participants With Favorable Per-Pathogen Microbiological Response by Pathogen Resistance Type at TOC Visit: ME Analysis Set

    Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable per-pathogen microbiological response by pathogen resistance type (ATM non-susceptible, Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.

    Time frame: At TOC visit (Day 28)

  25. Number of Participants According to Total Score for the Composite Endpoint of Symptom-Based Objective Clinical Measures: ITT Analysis Set

    Time frame: Up to Day 28

  26. Number of Participants According to Total Score for the Composite Endpoint of Symptom-Based Objective Clinical Measures: CE Analysis Set

    CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.

    Time frame: Up to Day 28

  27. Percentage of Participants Who Died on or Before 14 Days From Randomization: ITT Analysis Set

    Percentage of participants who died on or before 14 days from randomization is reported in this outcome measure.

    Time frame: From randomization up to 14 days

  28. Total Length of Hospital Stay up to TOC Visit: ITT Analysis Set

    The total length of hospital stay was defined as the total number of calendar days on which the participant was in the hospital from the date of randomization up to and including the specified time point of TOC.

    Time frame: From randomization up to Day 28

  29. Total Length of Hospital Stay up to TOC Visit: CE Analysis Set

    The total length of hospital stay was defined as the total number of calendar days on which the participant was in the hospital from the date of randomization up to and including the specified time point of TOC. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.

    Time frame: From randomization up to Day 28

  30. Duration of Study Treatment

    The duration of therapy in calendar days were calculated as follows: Date of last dose of study drug - date of first dose of study drug +1.

    Time frame: From first dose of study treatment until last dose of treatment (Up to 14 days)

  31. Length of Intensive Care Unit (ICU) Stay: ITT Analysis Set

    The total length of ICU stay was defined as the total number of calendar days on which the participant was in ICU for the period from date of randomization until the TOC visit.

    Time frame: From randomization until TOC visit (Up to Day 28)

  32. Length of Intensive Care Unit (ICU) Stay: CE Analysis Set

    The total length of ICU stay was defined as the total number of calendar days on which the participant was in ICU for the period from date of randomization until the TOC visit. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.

    Time frame: From randomization until TOC visit (Up to Day 28)

  33. Number of Participants Admitted to the ICU: ITT Analysis Set

    Number of participants admitted to the ICU up to TOC were reported in this outcome measure.

    Time frame: From randomization until TOC visit (Up to Day 28)

  34. Number of Participants Admitted to the ICU: CE Analysis Set

    The number of participants admitted to the ICU were reported in this outcome measure. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.

    Time frame: From randomization until TOC visit (Up to Day 28)

  35. Number of Participants With Mechanical Ventilation: ITT Analysis Set

    Number of participants with mechanical ventilation were reported in this outcome measure.

    Time frame: From randomization until TOC visit (Up to Day 28)

  36. Number of Participants With Mechanical Ventilation: CE Analysis Set

    Number of participants with mechanical ventilation were reported in this outcome measure. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.

    Time frame: From randomization until TOC visit (Up to Day 28)

  37. Duration of Mechanical Ventilation in HAP/VAP Participants: ITT Analysis Set

    Duration of mechanical ventilation was defined as the total number of calendar days on which the participant required mechanical ventilation from the date of randomization up to TOC.

    Time frame: From randomization until TOC visit (Up to Day 28)

  38. Duration of Mechanical Ventilation in HAP/VAP Participants: CE Analysis Set

    Duration of mechanical ventilation was defined as the total number of calendar days on which the participant required mechanical ventilation from the date of randomization up to TOC. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.

    Time frame: From randomization until TOC visit (Up to Day 28)

  39. Number of Participants With Unplanned Surgical Interventions in Complicated Intra-abdominal Infections (cIAI) Participants: ITT Analysis Set

    Unplanned surgical interventions was defined as those occurring after the initial qualifying surgical intervention and prior to the TOC visit. Number of cIAI participants with unplanned surgical intervention according to clinical response categories of cure and failure is reported in this outcome measure.

    Time frame: From randomization until TOC visit (Up to Day 28)

  40. Number of Participants With Unplanned Surgical Interventions in cIAI Participants: CE Analysis Set

    Unplanned surgical interventions was defined as those occurring after the initial qualifying surgical intervention and prior to the TOC visit. Number of cIAI participants with unplanned surgical intervention according to clinical response categories of cure and failure is reported in this outcome measure.

    Time frame: From randomization until TOC visit (Up to Day 28)

07

Results

Posted May 7, 2024

Participant flow

Participants who were hospitalized with a diagnosis of complicated intra-abdominal infection (cIAI) or nosocomial pneumonia (NP) including hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) were enrolled. This study was conducted across 20 countries from 05-Apr-2018 to 23-Feb-2023.

Participant flow — Overall Study
MilestoneAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Started282140
Participants with ciai208104
Participants with hap/vap7436
Completed242122
Not completed4018
Withdrew: Other22
Withdrew: Withdrawal by subject163
Withdrew: Physician decision10
Withdrew: Death1711
Withdrew: Adverse event31
Withdrew: Lost to follow-up11

Outcome measures

PrimaryPercentage of Participants With Clinical Cure at Test of Cure (TOC) Visit: Intent-To-Treat (ITT) Analysis Set

Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% confidence interval (CI) was based on Jeffrey's method.

Time frame:
At TOC visit (Day 28)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Cure at Test of Cure (TOC) Visit: Intent-To-Treat (ITT) Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Percentage of Participants With Clinical Cure at Test of Cure (TOC) Visit: Intent-To-Treat (ITT) Analysis Set68.4 (62.8 to 73.7)65.7 (57.6 to 73.2)
Statistical analysis
  • Aztreonam-avibactam ± Metronidazole vs Meropenem± Colistimethate · Difference in clinical cure rate: 2.7 · 95% CI -6.6 to 12.4The confidence interval (CI) for the difference was calculated using the unstratified Miettinen and Nurminen method.
PrimaryPercentage of Participants With Clinical Cure at TOC Visit: Clinically Evaluable (CE) Analysis Set

Clinical cure = improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method. CE analysis set:all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.

Time frame:
At TOC visit (Day 28)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Cure at TOC Visit: Clinically Evaluable (CE) Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Percentage of Participants With Clinical Cure at TOC Visit: Clinically Evaluable (CE) Analysis Set77.0 (71.0 to 82.3)74.3 (65.3 to 81.9)
Statistical analysis
  • Aztreonam-avibactam ± Metronidazole vs Meropenem± Colistimethate · Difference in clinical cure rate: 2.7 · 95% CI -7.0 to 13.2The CI for the difference was calculated using the unstratified Miettinen and Nurminen method.
SecondaryPercentage of Participants With Clinical Cure at TOC Visit: Microbiological Intent-To-Treat (Micro-ITT) Analysis Set

Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.

Time frame:
At TOC visit (Day 28)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Cure at TOC Visit: Microbiological Intent-To-Treat (Micro-ITT) Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Percentage of Participants With Clinical Cure at TOC Visit: Microbiological Intent-To-Treat (Micro-ITT) Analysis Set72.9 (66.0 to 79.0)72.3 (62.7 to 80.6)
Statistical analysis
  • Aztreonam-avibactam ± Metronidazole vs Meropenem± Colistimethate · Difference in clinical cure rate: 0.5 · 95% CI -10.2 to 12.1CI for the difference was calculated using the unstratified Miettinen and Nurminen method.
SecondaryPercentage of Participants With Clinical Cure at TOC Visit: Microbiologically Evaluable (ME) Analysis Set

Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.

Time frame:
At TOC visit (Day 28)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Cure at TOC Visit: Microbiologically Evaluable (ME) Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Percentage of Participants With Clinical Cure at TOC Visit: Microbiologically Evaluable (ME) Analysis Set78.5 (71.4 to 84.5)75.9 (65.7 to 84.3)
Statistical analysis
  • Aztreonam-avibactam ± Metronidazole vs Meropenem± Colistimethate · Difference in clinical cure rate: 2.6 · 95% CI -8.4 to 14.7CI for the difference was calculated using the unstratified Miettinen and Nurminen method.
SecondaryPercentage of Participants With Clinical Cure at TOC Visit by Type of Infection: ITT Analysis Set

Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.

Time frame:
At TOC visit (Day 28)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Cure at TOC Visit by Type of Infection: ITT Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
cIAI76.4 (70.3 to 81.8)74.0 (65.0 to 81.7)
HAP/VAP45.9 (34.9 to 57.3)41.7 (26.7 to 57.9)
Statistical analysis
  • Aztreonam-avibactam ± Metronidazole vs Meropenem± Colistimethate · Difference in clinical cure rate: 2.4 · 95% CI -7.4 to 13.0CI for the difference was calculated using the unstratified Miettinen and Nurminen method.
  • Aztreonam-avibactam ± Metronidazole vs Meropenem± Colistimethate · Difference · Difference in clinical cure rate: 4.3 · 95% CI -15.5 to 23.1CI for the difference was calculated using the unstratified Miettinen and Nurminen method.
SecondaryPercentage of Participants With Clinical Cure at TOC Visit by Type of Infection: CE Analysis Set

Clinical cure = improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method. CE analysis set:all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.

Time frame:
At TOC visit (Day 28)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Cure at TOC Visit by Type of Infection: CE Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
cIAI85.1 (79.2 to 89.9)79.5 (69.9 to 87.1)
HAP/VAP46.7 (32.7 to 61.1)54.5 (34.3 to 73.7)
Statistical analysis
  • Aztreonam-avibactam ± Metronidazole vs Meropenem± Colistimethate · Difference in clinical cure rate: 5.6 · 95% CI -4.0 to 16.6CI for the difference was calculated using the unstratified Miettinen and Nurminen method.
  • Aztreonam-avibactam ± Metronidazole vs Meropenem± Colistimethate · Difference in clinical cure rate: -7.9 · 95% CI -31.9 to 17.3CI for the difference was calculated using the unstratified Miettinen and Nurminen method.
SecondaryPercentage of Participants With Clinical Cure in Participants With Metallo-beta-lactamase (MBL) Positive Pathogen at TOC Visit: Micro-ITT Analysis Set

Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee.

Time frame:
At TOC visit (Day 28)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Cure in Participants With Metallo-beta-lactamase (MBL) Positive Pathogen at TOC Visit: Micro-ITT Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Percentage of Participants With Clinical Cure in Participants With Metallo-beta-lactamase (MBL) Positive Pathogen at TOC Visit: Micro-ITT Analysis Set28.666.7
SecondaryPercentage of Participants With Clinical Cure in Participants With MBL Positive Pathogen at TOC Visit: ME Analysis Set

Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee.

Time frame:
At TOC visit (Day 28)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Cure in Participants With MBL Positive Pathogen at TOC Visit: ME Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Percentage of Participants With Clinical Cure in Participants With MBL Positive Pathogen at TOC Visit: ME Analysis Set50.00
SecondaryPercentage of Participants With Favorable Per-Participant Microbiological Response at TOC Visit: Micro- ITT Analysis Set

Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure.

Time frame:
At TOC visit day (28)
Reported as:
Number · Percentage of participants
Percentage of Participants With Favorable Per-Participant Microbiological Response at TOC Visit: Micro- ITT Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Percentage of Participants With Favorable Per-Participant Microbiological Response at TOC Visit: Micro- ITT Analysis Set75.773.9
SecondaryPercentage of Participants With Favorable Per-Participant Microbiological Response at TOC Visit: ME Analysis Set

Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure.

Time frame:
At TOC Visit (Day 28)
Reported as:
Number · Percentage of participants
Percentage of Participants With Favorable Per-Participant Microbiological Response at TOC Visit: ME Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Percentage of Participants With Favorable Per-Participant Microbiological Response at TOC Visit: ME Analysis Set77.275.9
SecondaryPercentage of Participants Who Died on or Before 28 Days After Randomization: ITT Analysis Set

Percentage of participants who died on or before 28 days after randomization is reported in this outcome measure.

Time frame:
From randomization up to 28 days
Reported as:
Number · Percentage of participants
Percentage of Participants Who Died on or Before 28 Days After Randomization: ITT Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Percentage of Participants Who Died on or Before 28 Days After Randomization: ITT Analysis Set4.37.1
SecondaryPercentage of Participants Who Died on or Before 28 Days After Randomization: Micro-ITT Analysis Set

Percentage of participants who died on or before 28 days after randomization is reported in this outcome measure.

Time frame:
From randomization up to 28 days
Reported as:
Number · Percenatge of participants
Percentage of Participants Who Died on or Before 28 Days After Randomization: Micro-ITT Analysis Set
Percenatge of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Percentage of Participants Who Died on or Before 28 Days After Randomization: Micro-ITT Analysis Set2.86.4
SecondaryPlasma Concentration of Aztreonam

Plasma concentration for aztreonam according to renal function (augmented, normal and mild, moderate and severe is presented in this outcome measure. Augmented = Creatinine clearance (CrCL) \> 150 milliliters per minute (mL/min); Normal \& Mild = CrCL \> 50 to \<=150 mL/min; Moderate = CrCL \> 30 to ≤ 50 mL/min; Severe = CrCL \> 15 to ≤ 30 mL/min.

Time frame:
Anytime between 25 to 30 minutes, 3.25 to 3.5 hours, 5.5 to 6.5 hours, 7.5 to 8.5 hours post start of infusion on Day 1; 2.75 to 3 hours, 3.5 to 4.5 hours, 5 to 6 and 7 to 8 hours post start of infusion on Day 4
Reported as:
Geometric mean · Milligram/Liter
Plasma Concentration of Aztreonam
Milligram/LiterAztreonam-avibactam ± Metronidazole
Renal Function: Augmented:25 to 30 minutes post start of infusion on Day 143.3 ± 339.08
Renal Function: Augmented:3.25 to 3.5 hours post start of infusion on Day 155.99 ± 287.36
Renal Function: Augmented: 5.5 hours to 6.5 hours post loading infusion on Day 126.11 ± 338.5
Renal Function: Normal & Mild: 25 to 30 min post start of infusion on Day 133.85 ± 234.46
Renal Function: Normal & Mild:3.25 to 3.5 hours post start of infusion on Day 156.24 ± 222.32
Renal Function: Normal & Mild:5.5 hours to 6.5 hours post start of infusion on Day 125.03 ± 115.83
Renal Function: Normal & Mild:7.5 to 8.5 hours post start of infusion on Day 134.62 ± 54.42
Renal Function: Moderate: 25 to 30 min post start of infusion on Day 154.49 ± 313.99
Renal Function: Moderate: 3.25 to 3.5 hours post start of infusion on Day 173.72 ± 259.64
Renal Function: Moderate: 5.5 hours to 6.5 hours post start of infusion on Day 152.45 ± 139.9
Renal Function: Moderate: 7.5 to 8.5 hours post start of infusion on Day 134 ± NA
Renal Function: Severe: 25 to 30 min post start of infusion on Day 148.98 ± 187.86
Renal Function: Severe: 3.25 to 3.5 hours post start of infusion on Day 150.31 ± 30.13
Renal Function: Severe: 5.5 hours to 6.5 hours post start of infusion on Day 148.54 ± 46.87
Renal Function: Severe: 7.5 to 8.5 hours post start of infusion on Day 129.42 ± 34.88
Renal Function: Augmented: 2.75 to 3 hours post start of infusion on Day 446.11 ± 234.31
Renal Function: Augmented: 3.5 to 4.5 hours post start of infusion on Day 433.56 ± 204.99
Renal Function: Augmented: 5 to 6 hours post start of infusion on Day 419.56 ± 205.84
Renal Function: Augmented: 7 to 8 hours post start of infusion on Day 414.1 ± NA
Renal Function: Normal & Mild: 2.75 to 3 hours post start of infusion on Day 456.59 ± 404.54
Renal Function: Normal & Mild: 3.5 to 4.5 hours post start of infusion on Day 435.69 ± 422.52
Renal Function: Normal & Mild: 5 to 6 hours post start of infusion on Day 421.75 ± 271.62
Renal Function: Normal & Mild: 7 to 8 hours post start of infusion on Day 442.98 ± 62.54
Renal Function: Moderate: 2.75 to 3 hours post start of infusion on Day 473.33 ± 183.2
Renal Function: Moderate: 3.5 to 4.5 hours post start of infusion on Day 458 ± 129.36
Renal Function: Moderate: 5 to 6 hours post start of infusion on Day 444.72 ± 59.15
Renal Function: Moderate: 7 to 8 hours post start of infusion on Day 419.8 ± NA
Renal Function: Severe: 2.75 to 3 hours post start of infusion on Day 454.91 ± 45.17
Renal Function: Severe: 3.5 to 4.5 hours post start of infusion on Day 445.17 ± 34.89
Renal Function: Severe: 5 to 6 hours post start of infusion on Day 445.11 ± 57.13
Renal Function: Severe:7 to 8 hours post start of infusion on Day 432.69 ± 55.56
SecondaryPlasma Concentration of Avibactam

Plasma concentration for avibactam according to renal function (augmented, normal and mild, moderate and severe is presented in this outcome measure. Augmented = CrCL \> 150 mL/min; Normal \& Mild = CrCL \> 50 to \<=150 mL/min; Moderate = CrCL \> 30 to ≤ 50 mL/min; Severe = CrCL \> 15 to ≤ 30 mL/min.

Time frame:
Anytime between 25 to 30 minutes, 3.25 to 3.5 hours, 5.5 to 6.5 hours, 7.5 to 8.5 hours post start of infusion on Day 1; 2.75 to 3 hours, 3.5 to 4.5 hours, 5 to 6 and 7 to 8 hours post start of infusion on Day 4
Reported as:
Geometric mean · Milligram/Liter
Plasma Concentration of Avibactam
Milligram/LiterAztreonam-avibactam ± Metronidazole
Renal Function: Augmented:25 to 30 minutes post start of infusion on Day 110.77 ± 353.86
Renal Function: Augmented:3.25 to 3.5 hours post start of infusion on Day 112.6 ± 299.27
Renal Function: Augmented: 5.5 hours to 6.5 hours post start of infusion on Day 14.75 ± 366.33
Renal Function: Normal & Mild: 25 to 30 min post start of infusion on Day 18.81 ± 338.73
Renal Function: Normal & Mild:3.25 to 3.5 hours post start of infusion on Day 113.76 ± 242.67
Renal Function: Normal & Mild:5.5 hours to 6.5 hours post start of infusion on Day 14.85 ± 209.49
Renal Function: Normal & Mild:7.5 to 8.5 hours post start of infusion on Day 17.18 ± 62.62
Renal Function: Moderate: 25 to 30 min post start of infusion on Day 113.56 ± 383.79
Renal Function: Moderate: 3.25 to 3.5 hours post start of infusion on Day 120.28 ± 262.6
Renal Function: Moderate: 5.5 hours to 6.5 hours post start of infusion on Day 113.47 ± 160.75
Renal Function: Moderate: 7.5 to 8.5 hours post start of infusion on Day 17.91 ± NA
Renal Function: Severe: 25 to 30 min post start of infusion on Day 114.11 ± 202.08
Renal Function: Severe: 3.25 to 3.5 hours post start of infusion on Day 113.62 ± 39.68
Renal Function: Severe: 5.5 hours to 6.5 hours post start of infusion on Day 111.6 ± 54.34
Renal Function: Severe: 7.5 to 8.5 hours post start of infusion on Day 18 ± 57.91
Renal Function: Augmented: 2.75 to 3 hours post start of infusion on Day 49.75 ± 289.96
Renal Function: Augmented: 3.5 to 4.5 hours post start of infusion on Day 46.23 ± 263.94
Renal Function: Augmented: 5 to 6 hours post start of infusion on Day 43.19 ± 265.65
Renal Function: Augmented: 7 to 8 hours post start of infusion on Day 42.72 ± NA
Renal Function: Normal & Mild: 2.75 to 3 hours post start of infusion on Day 411.46 ± 504.77
Renal Function: Normal & Mild: 3.5 to 4.5 hours post start of infusion on Day 46.29 ± 493.48
Renal Function: Normal & Mild: 5 to 6 hours post start of infusion on Day 43.48 ± 382.3
Renal Function: Normal & Mild: 7 to 8 hours post start of infusion on Day 46.19 ± 51.22
Renal Function: Moderate: 2.75 to 3 hours post start of infusion on Day 416.98 ± 208.63
Renal Function: Moderate: 3.5 to 4.5 hours post start of infusion on Day 412.86 ± 156.96
Renal Function: Moderate: 5 to 6 hours post start of infusion on Day 49.23 ± 72.89
Renal Function: Moderate: 7 to 8 hours post start of infusion on Day 44.35 ± NA
Renal Function: Severe: 2.75 to 3 hours post start of infusion on Day 414.35 ± 44.72
Renal Function: Severe: 3.5 to 4.5 hours post start of infusion on Day 411.68 ± 42.15
Renal Function: Severe: 5 to 6 hours post start of infusion on Day 49.99 ± 67.87
Renal Function: Severe: Moderate: 7 to 8 hours post start of infusion on Day 48.97 ± 47.28
SecondaryMaximum Plasma Concentration for a Dosing Interval at Steady-State (Cmax, ss) According to Clinical Response by Infection Type at TOC: Aztreonam

Population PK predicted maximum plasma concentration for a dosing interval at steady-state (Cmax,ss) for participants who received aztreonam-avibactam in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Clinical response categories included, clinical cure=improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Failure was defined as participants who met any of the following criteria like death (after receiving at least 48 hours of study treatment) and participants who received treatment with further antibiotics for the index infection. Indeterminate was defined as death (after receiving less than 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.

Time frame:
At TOC (Day 28)
Reported as:
Geometric mean · Milligram per liter (mg/L)
Maximum Plasma Concentration for a Dosing Interval at Steady-State (Cmax, ss) According to Clinical Response by Infection Type at TOC: Aztreonam
Milligram per liter (mg/L)Aztreonam- Avibactam
cIAI: Clinical cure52.47 ± 37.49
cIAI: Failure56.71 ± 62.52
cIAI: Indeterminate66.21 ± 12.7
HAP:Clinical cure85.24 ± 48.49
HAP: Failure64.57 ± 33.97
HAP: Indeterminate61.79 ± 27.2
VAP: Clinical Cure54.89 ± 30.42
VAP: Failure56.5 ± 31.1
VAP: Indeterminate85.34 ± NA
SecondaryPercentage of Time That Free Plasma Concentrations Are Above the Minimum Inhibitory Concentration Over a Dosing Interval (%fT>MIC Aztreonam (ATM) of 8 mg/L) According to Clinical Response by Infection Type at TOC: Aztreonam

Population PK predicted (%fT\>MIC ATM of 8 mg/L) for participants who received aztreonam-avibactam in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Clinical response categories included, clinical cure=improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Failure was defined as participants who met any of the following criteria like death (after receiving at least 48 hours of study treatment) and participants who received treatment with further antibiotics for the index infection. Indeterminate was defined as death (after receiving less than 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.

Time frame:
At TOC (Day 28)
Reported as:
Geometric mean · Percentage of time
Percentage of Time That Free Plasma Concentrations Are Above the Minimum Inhibitory Concentration Over a Dosing Interval (%fT>MIC Aztreonam (ATM) of 8 mg/L) According to Clinical Response by Infection Type at TOC: Aztreonam
Percentage of timeAztreonam- Avibactam
cIAI: Clinical cure90.4 ± 41.9
cIAI: Failure73.81 ± 134.39
cIAI: Indeterminate100 ± 0
HAP:Clinical cure97.87 ± 7.67
HAP: Failure97.2 ± 8.4
HAP: Indeterminate100 ± 0
VAP: Clinical Cure95.29 ± 8.94
VAP: Failure96.38 ± 10.02
VAP: Indeterminate100 ± NA
SecondaryArea Under the Plasma Concentration-time Curve Over 24 Hours at Steady-state (AUC24,ss ) According to Clinical Response by Infection Type at TOC: Aztreonam

Population PK predicted (AUC24,ss) for participants who received aztreonam-avibactam in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Clinical response categories included, clinical cure=improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Failure was defined as participants who met any of the following criteria like death (after receiving at least 48 hours of study treatment) and participants who received treatment with further antibiotics for the index infection. Indeterminate was defined as death (after receiving less than 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.

Time frame:
0 to 24 hours at TOC (Day 28)
Reported as:
Geometric mean · Milligram*hours per liter (mg*h/L)
Area Under the Plasma Concentration-time Curve Over 24 Hours at Steady-state (AUC24,ss ) According to Clinical Response by Infection Type at TOC: Aztreonam
Milligram*hours per liter (mg*h/L)Aztreonam- Avibactam
cIAI: Clinical cure816.18 ± 41.83
cIAI: Failure877.5 ± 85.91
cIAI: Indeterminate1069.1 ± 15.82
HAP:Clinical cure1420.1 ± 54.62
HAP: Failure1079.4 ± 34.1
HAP: Indeterminate1056.8 ± 35.68
VAP: Clinical cure858.39 ± 32.49
VAP: Failure912.23 ± 38.1
VAP: Indeterminate1084.6 ± NA
SecondaryMaximum Plasma Concentration for a Dosing Interval at Steady-state (Cmax,ss) According to Microbiological Response by Infection Type at TOC: Aztreonam

Population PK predicted (Cmax,ss) for participants who received ATM-AVI in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Microbiological response included Favorable =baseline pathogens for participant had a favorable outcome. Eradication: Absence of causative pathogen from an appropriately obtained specimen at site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Unfavorable=persistence, persistence with increasing MIC, or presumed persistence. Persistence= Causative organism still present from appropriately obtained specimen at site of infection. Presumed persistence= Participant assessed as a clinical failure and repeat culture of specimens were not performed/clinically indicated. Indeterminate = death (after receiving \< 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.

Time frame:
At TOC (Day 28)
Reported as:
Geometric mean · Milligram per liter (mg/L)
Maximum Plasma Concentration for a Dosing Interval at Steady-state (Cmax,ss) According to Microbiological Response by Infection Type at TOC: Aztreonam
Milligram per liter (mg/L)Aztreonam- Avibactam
cIAI: Favorable53.26 ± 34.03
cIAI: Unfavorable53.71 ± 67.14
cIAI: Indeterminate62.97 ± 9.49
HAP:Favorable86.9 ± 71.56
HAP: Unfavorable55.48 ± 38.83
HAP: Indeterminate66.2 ± 33.87
VAP: Favorable50.71 ± 37.56
VAP: Unfavorable59.77 ± 31.52
VAP: Indeterminate85.34 ± NA
SecondaryArea Under the Plasma Concentration-time Curve Over 24 Hours at Steady-state (AUC24,ss) According to Microbiological Response by Infection Type at TOC: Aztreonam

Population PK predicted (AUC24,ss) for participants who received ATM-AVI in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Microbiological response included Favorable =baseline pathogens for participant had a favorable outcome. Eradication: Absence of causative pathogen from an appropriately obtained specimen at site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Unfavorable=persistence, persistence with increasing MIC, or presumed persistence. Persistence= Causative organism still present from appropriately obtained specimen at site of infection. Presumed persistence= Participant assessed as a clinical failure and repeat culture of specimens were not performed/clinically indicated. Indeterminate = death (after receiving \< 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.

Time frame:
0 to 24 hours at TOC (Day 28)
Reported as:
Geometric mean · Milligram*hours per liter
Area Under the Plasma Concentration-time Curve Over 24 Hours at Steady-state (AUC24,ss) According to Microbiological Response by Infection Type at TOC: Aztreonam
Milligram*hours per literAztreonam- Avibactam
cIAI: Favorable830.23 ± 38.42
cIAI: Unfavorable826.63 ± 95.22
cIAI: Indeterminate1010.2 ± 9.17
HAP:Favorable1446.1 ± 82.6
HAP: Unfavorable909.59 ± 45.06
HAP: Indeterminate1237.9 ± 38.16
VAP: Favorable760.26 ± 40.54
VAP: Unfavorable974.21 ± 37.82
VAP: Indeterminate1084.6 ± NA
SecondaryPercentage of Time That Free Plasma Concentrations Are Above the Minimum Inhibitory Concentration Over a Dosing Interval (%fT>MIC Aztreonam (ATM) of 8 mg/L) According to Microbiological Response by Infection Type at TOC: Aztreonam

Population PK predicted (%fT\>MIC ATM of 8 mg/L) for participants who received ATM-AVI in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Microbiological response included Favorable =baseline pathogens for participant had a favorable outcome. Eradication: Absence of causative pathogen from an appropriately obtained specimen at site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Unfavorable=persistence, persistence with increasing MIC, or presumed persistence. Persistence= Causative organism still present from appropriately obtained specimen at site of infection. Presumed persistence= Participant assessed as a clinical failure and repeat culture of specimens were not performed/clinically indicated. Indeterminate = death (after receiving \< 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.

Time frame:
At TOC (Day 28)
Reported as:
Geometric mean · Percentage of time
Percentage of Time That Free Plasma Concentrations Are Above the Minimum Inhibitory Concentration Over a Dosing Interval (%fT>MIC Aztreonam (ATM) of 8 mg/L) According to Microbiological Response by Infection Type at TOC: Aztreonam
Percentage of timeAztreonam- Avibactam
cIAI: Favorable92.57 ± 17.66
cIAI: Unfavorable68.02 ± 171.87
cIAI: Indeterminate100 ± 0
HAP:Favorable95.53 ± 11.05
HAP: Unfavorable93.9 ± 14.14
HAP: Indeterminate100 ± 0
VAP: Favorable90.8 ± 12.3
VAP: Unfavorable97.42 ± 9.54
VAP: Indeterminate100 ± NA
SecondaryArea Under the Plasma Concentration-time Curve Over 24 Hours at Steady-state (AUC24,ss) According to Clinical Response by Infection Type at TOC: Avibactam

Population PK predicted (AUC24,ss) for participants who received aztreonam-avibactam in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Clinical response categories included, clinical cure=improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Failure was defined as participants who met any of the following criteria like death (after receiving at least 48 hours of study treatment) and participants who received treatment with further antibiotics for the index infection. Indeterminate was defined as death (after receiving less than 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.

Time frame:
0 to 24 hours at TOC (Day 28)
Reported as:
Geometric mean · Milligram*hour per liter
Area Under the Plasma Concentration-time Curve Over 24 Hours at Steady-state (AUC24,ss) According to Clinical Response by Infection Type at TOC: Avibactam
Milligram*hour per literAztreonam- Avibactam
cIAI: Clinical cure164.92 ± 45.91
cIAI: Failure187.41 ± 96.93
cIAI: Indeterminate213.92 ± 20.81
HAP:Clinical cure291.47 ± 61.75
HAP: Failure214.99 ± 36.09
HAP: Indeterminate257.37 ± 71.75
VAP: Clinical cure176.95 ± 31.43
VAP: Failure178.68 ± 38.99
VAP: Indeterminate218.09 ± NA
SecondaryMaximum Plasma Concentration for a Dosing Interval at Steady-state (Cmax,ss ) According to Clinical Response by Infection Type at TOC: Avibactam

Population PK predicted (Cmax,ss) for participants who received aztreonam-avibactam in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Clinical response categories included, clinical cure=improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Failure was defined as participants who met any of the following criteria like death (after receiving at least 48 hours of study treatment) and participants who received treatment with further antibiotics for the index infection. Indeterminate was defined as death (after receiving less than 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.

Time frame:
At TOC (Day 28)
Reported as:
Geometric mean · Milligram per liter (mg/L)
Maximum Plasma Concentration for a Dosing Interval at Steady-state (Cmax,ss ) According to Clinical Response by Infection Type at TOC: Avibactam
Milligram per liter (mg/L)Aztreonam- Avibactam
cIAI: Clinical cure11.01 ± 42.14
cIAI: Failure12.48 ± 72.59
cIAI: Indeterminate14.04 ± 16.52
HAP:Clinical cure18.41 ± 55.07
HAP: Failure13.46 ± 33.52
HAP: Indeterminate15.24 ± 49.1
VAP: Clinical Cure11.64 ± 31.01
VAP: Failure11.44 ± 32.65
VAP: Indeterminate18.93 ± NA
SecondaryPercent of Time That Free Plasma Concentrations Are Above the Threshold Concentration Over a Dosing Interval (%fT>CT of 2.5mg/L) According to Clinical Response by Infection Type at TOC: Avibactam

Population PK predicted (%fT\>CT of 2.5mg/L) for participants who received aztreonam-avibactam in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Clinical response categories included, clinical cure=improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Failure was defined as participants who met any of the following criteria like death (after receiving at least 48 hours of study treatment) and participants who received treatment with further antibiotics for the index infection. Indeterminate was defined as death (after receiving less than 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.

Time frame:
At TOC (Day 28)
Reported as:
Geometric mean · Percentage of time
Percent of Time That Free Plasma Concentrations Are Above the Threshold Concentration Over a Dosing Interval (%fT>CT of 2.5mg/L) According to Clinical Response by Infection Type at TOC: Avibactam
Percentage of timeAztreonam- Avibactam
cIAI: Clinical cure85.53 ± 43.26
cIAI: Failure71.92 ± 133.68
cIAI: Indeterminate98.52 ± 2.81
HAP:Clinical cure95.99 ± 11.57
HAP: Failure95.28 ± 12.12
HAP: Indeterminate92.75 ± 11.19
VAP: Clinical Cure92 ± 13.01
VAP: Failure94.08 ± 12.93
VAP: Indeterminate100 ± NA
SecondaryArea Under the Plasma Concentration-time Curve Over 24 Hours at Steady-state (AUC24,ss) According to Microbiological Response by Infection Type at TOC: Avibactam

Population PK predicted (AUC24,ss) for participants who received ATM-AVI in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Microbiological response included Favorable =baseline pathogens for participant had a favorable outcome. Eradication: Absence of causative pathogen from an appropriately obtained specimen at site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Unfavorable=persistence, persistence with increasing MIC, or presumed persistence. Persistence= Causative organism still present from appropriately obtained specimen at site of infection. Presumed persistence= Participant assessed as a clinical failure and repeat culture of specimens were not performed/clinically indicated. Indeterminate = death (after receiving\<48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.

Time frame:
0 to 24 hours At TOC (Day 28)
Reported as:
Geometric mean · Milligram*hours per liter
Area Under the Plasma Concentration-time Curve Over 24 Hours at Steady-state (AUC24,ss) According to Microbiological Response by Infection Type at TOC: Avibactam
Milligram*hours per literAztreonam- Avibactam
cIAI: Favorable166.4 ± 40.88
cIAI: Unfavorable177.65 ± 106.25
cIAI: Indeterminate197.01 ± 7.31
HAP:Favorable293.49 ± 95.13
HAP: Unfavorable196.38 ± 61.95
HAP: Indeterminate359.31 ± 71.12
VAP: Favorable157.79 ± 43.71
VAP: Unfavorable192.85 ± 38.42
VAP: Indeterminate218.09 ± NA
SecondaryMaximum Plasma Concentration for a Dosing Interval at Steady-state (Cmax,ss (mg/L)) According to Microbiological Response by Infection Type at TOC: Avibactam

Population PK predicted (Cmax,ss (mg/L)) for participants who received ATM-AVI in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Microbiological response included Favorable =baseline pathogens for participant had a favorable outcome. Eradication: Absence of causative pathogen from an appropriately obtained specimen at site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Unfavorable=persistence, persistence with increasing MIC, or presumed persistence. Persistence= Causative organism still present from appropriately obtained specimen at site of infection. Presumed persistence= Participant assessed as a clinical failure and repeat culture of specimens were not performed/clinically indicated. Indeterminate = death (after receiving\<48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.

Time frame:
At TOC (Day 28)
Reported as:
Geometric mean · Milligram per liter (mg/L)
Maximum Plasma Concentration for a Dosing Interval at Steady-state (Cmax,ss (mg/L)) According to Microbiological Response by Infection Type at TOC: Avibactam
Milligram per liter (mg/L)Aztreonam- Avibactam
cIAI: Favorable11.1 ± 37.2
cIAI: Unfavorable11.83 ± 76.48
cIAI: Indeterminate13.03 ± 8.01
HAP:Favorable18.55 ± 84.68
HAP: Unfavorable12.31 ± 51.34
HAP: Indeterminate18.72 ± 55.03
VAP: Favorable10.75 ± 42.72
VAP: Unfavorable12.28 ± 32.85
VAP: Indeterminate18.93 ± NA
SecondaryPercent of Time That Free Plasma Concentrations Are Above the Threshold Concentration Over a Dosing Interval; (%fT>CT of 2.5 mg/L) According to Microbiological Response by Infection Type at TOC: Avibactam

Population PK predicted (%fT\>CT of 2.5 mg/L) for participants who received ATM-AVI in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Microbiological response included Favorable =baseline pathogens for participant had a favorable outcome. Eradication: Absence of causative pathogen from an appropriately obtained specimen at site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Unfavorable=persistence, persistence with increasing MIC, or presumed persistence. Persistence= Causative organism still present from appropriately obtained specimen at site of infection. Presumed persistence= Participant assessed as a clinical failure and repeat culture of specimens were not performed/clinically indicated. Indeterminate = death (after receiving \< 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.

Time frame:
At TOC (Day 28)
Reported as:
Geometric mean · Percentage of time
Percent of Time That Free Plasma Concentrations Are Above the Threshold Concentration Over a Dosing Interval; (%fT>CT of 2.5 mg/L) According to Microbiological Response by Infection Type at TOC: Avibactam
Percentage of timeAvibactam
cIAI: Favorable87.93 ± 21.78
cIAI: Unfavorable66.43 ± 170.59
cIAI: Indeterminate99.24 ± 1.52
HAP:Favorable92.26 ± 16.44
HAP: Unfavorable90.03 ± 18.83
HAP: Indeterminate100 ± 0
VAP: Favorable87.47 ± 16.8
VAP: Unfavorable95.52 ± 11.79
VAP: Indeterminate100 ± NA
SecondaryNumber of Participants With Adverse Events (AEs) and Serious AEs

An adverse event (AE) was any untoward medical occurrence in a study participant administered medicinal product,; the event need not necessarily have a causal relationship with product treatment or usage. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital abnormal/birth defect or considered an important medical event.

Time frame:
From start of study treatment until end of late follow-up (Up to Day 45)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious AEs
ParticipantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
AEs17787
SAEs5325
SecondaryNumber of Participants With Potentially Clinically Significant Hematology Abnormalities

Criteria for potential clinically significant hematology results were as follows: hemoglobin, hematocrit and erythrocyte \<0.7\*lower limit of normal \[LLN\] and \>30% decrease from Baseline (DFB); \>1.3\*upper limit of normal (ULN) and \>30% increase from Baseline (IFB). Platelet count \<0.65\*LLN and \> 50% decrease from baseline; \> 1.5 \* ULN and \> 100% increase from baseline. leukocyte: \< 0.65\* LLN and \> 60% decrease from baseline; \> 1.5\* ULN and 100% increase from baseline. Neutrophils/leukocytes \< 0.65 \* LLN and \>75% decrease from baseline; \> 1.6\*ULN and \> 100% increase from baseline. Lymphocytes/leukocytes \< 0.25\* LLN and \> 75% decrease from baseline;\> 1.5\* ULN and \> 100% increase from baseline, Eosinophils/leukocytes, Monocytes/leukocytes, Basophils/leukocytes \> 4.0\* ULN and \> 300% increase from baseline.

Time frame:
From start of study treatment until TOC visit (Up to Day 28)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Hematology Abnormalities
ParticipantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Hematocrit < 0.7*LLN and > 30% Decrease from Baseline63
Hematocrit > 1.3* ULN and > 30% Increase from Baseline00
Hemoglobin< 0.7* LLN and > 30% Decrease from Baseline83
Hemoglobin > 1.3* ULN and > 30% Increase from Baseline00
Erythrocytes < 0.7* LLN and > 30% Decrease from Baseline73
Erythrocytes > 1.3* ULN and > 30% Increase from Baseline00
Leukocytes < 0.65* LLN and > 60% Decrease from Baseline00
Leukocytes > 1.5* ULN and > 100% Increase from Baseline125
Neutrophils/Leukocytes < 0.65* LLN and > 75% Decrease from Baseline00
Neutrophils/Leukocytes > 1.6* ULN and > 100% Increase from Baseline00
Monocytes/Leukocytes > 4.0* ULN and > 300% Increase from Baseline00
Lymphocytes/Leukocytes < 0.25* LLN and > 75% Decrease from Baseline11
Lymphocytes/Leukocytes > 1.5* ULN and > 100% Increase from Baseline00
Eosinophils/Leukocytes > 4.0* ULN and > 300% Increase from Baseline00
Basophils/Leukocytes > 4.0* ULN and > 300% Increase from Baseline00
Platelets < 0.65* LLN and > 50% Decrease from Baseline32
Platelets > 1.5* ULN and > 100% Increase from Baseline127
SecondaryNumber of Participants With Potentially Clinically Significant Clinical Chemistry Abnormalities

Albumin \< 0.5\* LLN and\> 50% decrease from baseline (DFB);\> 1.5 \* ULN and\> 50% increase from baseline (IFB). Alkaline phosphatase \< 0.5 \* LLN and\> 80% DFB;\> 3.0 \* ULN and\> 100%. Alanine and Aspartate aminotransferase \> 3.0 \* ULN and\> 100% IFB. Bicarbonate \< 0.7 \* LLN and \> 40% DFB;\> 1.3 \* ULN and\> 40% IFB. Blood urea nitrogen \< 0.2 \* LLN and \> 100% DFB; \> 3.0 \* ULN and \> 200% IFB. Calcium \< 0.7 \* LLN and \> 30% DFB;\> 1.3 \* ULN and\> 30% IFB. Chloride \< 0.8 \* LLN \>and 20% DFB; \> 1.2 \* ULN and \> 20% IFB. Creatinine \> 2.0 \* ULN and\> 100% IFB; Glucose \< 0.6 \* LLN and\> 40% DFB; \> 3.0 \* ULN and\> 200% IFB. Potassium \< 0.8 \* LLN and \> 20% DFB; \> 1.2 \* ULN and\> 20% IFB. Sodium \< 0.85 \* LLN and\> 10% DFB;\> 1.1 \* ULN and \>10% IFB. Bilirubin \> 1.5 \* ULN and \> 100% IFB.; Direct bilirubin \> 2.0 \* ULN and \> 150% IFB.

Time frame:
From start of study treatment until At TOC visit (Up to Day 28)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Clinical Chemistry Abnormalities
ParticipantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Aspartate Aminotransferase >3.0* ULN and > 100% Increase from Baseline2514
Alanine Aminotransferase > 3.0* ULN and > 100% Increase from Baseline2410
Alkaline Phosphatase < 0.5* LLN and > 80% Decrease from Baseline00
Alkaline Phosphatase > 3.0* ULN and > 100% Increase from Baseline54
Bilirubin > 1.5* ULN and > 100% Increase from Baseline23
Direct Bilirubin > 2.0* ULN and > 150% Increase from Baseline20
Creatinine > 2.0* ULN and > 100% Increase from Baseline03
Sodium < 0.85* LLN and > 10% Decrease from Baseline00
Sodium> 1.1* ULN and > 10% Increase from Baseline00
Potassium < 0.8* LLN and > 20% Decrease from Baseline61
Potassium > 1.2* ULN and > 20% Increase from Baseline54
Chloride< 0.8* LLN and > 20% Decrease from Baseline00
Chloride > 1.2* ULN and > 20% Increase from Baseline10
Bicarbonate < 0.7* LLN and > 40% Decrease from Baseline00
Bicarbonate > 1.3* ULN and > 40% Increase from Baseline31
Calcium < 0.7* LLN and > 30% Decrease from Baseline21
Calcium > 1.3* ULN and > 30% Increase from Baseline00
Albumin < 0.5* LLN and > 50% Decrease from Baseline00
Albumin > 1.5* ULN and > 50% Increase from Baseline00
Glucose < 0.6* LLN and > 40% Decrease from Baseline01
Glucose > 3.0* ULN and > 200% Increase from Baseline20
Urea Nitrogen < 0.2* LLN and > 100% Decrease from Baseline00
Urea Nitrogen > 3.0* ULN and > 200% Increase from Baseline00
SecondaryNumber of Participants With Abnormalities in Vital Signs

Vitals signs, included blood pressure and, heart rate. Blood pressure (BP) and heart rate were measured using a semiautomatic BP recording device with the participant in a supine position after at least 10 minutes of rest. Criteria for abnormalities included: Systolic BP (millimeters of mercury \[mmHg\]): value more than (\>) 150 and increase from baseline more than equal (\>= 30) or value less than (\<) 90 and decrease from baseline \>= 30; DBP: value \> 100 and increase from baseline \>=20 or Value \< 50 and decrease from baseline \>= 20; Heart Rate (beats per minute \[BPM\]): value \< 40 or \> 120.

Time frame:
From start of study treatment until TOC visit (Up to Day 28)
Reported as:
Count of participants · Participants
Number of Participants With Abnormalities in Vital Signs
ParticipantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Systolic BP (mmHg) Value more than (>) 150 and increase from baseline more than equal (≥ to 30)3516
Systolic BP (mmHg) Value less than (<) 90 and decrease from baseline more than equal (≥) 3083
Diastolic BP (mmHg) Value > 100 and increase from baseline ≥ 2080
Diastolic BP (mmHg) Value < 50 and decrease from baseline ≥ 20105
Heart Rate (BPM) Value < 40 or > 120265135
SecondaryNumber of Participants With Abnormal Physical Examination Finding

A complete physical examination was performed and included an assessment of the following: general appearance including site of infection, skin, head and throat (head, eyes, ears, nose, and throat), lymph nodes, lungs, cardiovascular (CV), abdomen, musculoskeletal, and neurological systems.

Time frame:
Screening, End of treatment (up to 24 hours post infusion on Day 14) and Test of Cure (Day 28)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Physical Examination Finding
ParticipantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Abdomen: Screening184103
Abdomen: End of Treatment5630
Abdomen: Test of Cure3112
Cardiovascular: Screening5022
Cardiovascular: End of Treatment2714
Cardiovascular: Test of Cure2010
Ears: Screening11
Ears: End of Treatment01
Ears:Test of Cure01
Eyes: Screening134
Eyes End of Treatment71
Eyes: Test of Cure61
General appearance: Screening7735
General appearance: End of Treatment3415
General appearance: Test of Cure168
Head: Screening124
Head: End of Treatment105
Head: Test of Cure62
Lungs: Screening7037
Lungs: End of Treatment4515
Lungs: Test of Cure228
Lymph nodes: Screening10
Lymph nodes: End of Treatment10
Lymph nodes: Test of Cure00
Musculoskeletal: Screening2110
Musculoskeletal: End of Treatment179
Musculoskeletal: Test of Cure93
Neurological: Screening3713
Neurological: End of Treatment349
Neurological: Test of Cure176
Nose: Screening43
Nose: End of Treatment20
Nose: Test of Cure10
Skin: Screening4725
Skin: End of Treatment3322
Skin: Test of Cure2112
Throat: Screening90
Throat: End of Treatment101
Throat: Test of Cure41
SecondaryNumber of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings

Standard 12-lead ECGs were recorded with the participants in the supine position after the participant had rested in this position for 10 minutes. Clinically significant findings were based on investigators assessment.

Time frame:
Baseline (latest non-missing value before start of treatment) and Day 3
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings
ParticipantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Baseline165
Day 3116
Other pre-specifiedPercentage of Participants With Clinical Cure at End of Treatment (EOT) Visit: ITT Analysis Set

Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.

Time frame:
At EOT visit (Within 24 hours after last infusion on Day 14)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Cure at End of Treatment (EOT) Visit: ITT Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Percentage of Participants With Clinical Cure at End of Treatment (EOT) Visit: ITT Analysis Set75.9 (70.6 to 80.6)73.6 (65.8 to 80.3)
Statistical analysis
  • Aztreonam-avibactam ± Metronidazole vs Meropenem± Colistimethate · Difference in clinical cure rate: 2.3 · 95% CI -6.2 to 11.5CI for the difference was calculated using the unstratified Miettinen and Nurminen method.
Other pre-specifiedPercentage of Participants With Clinical Cure at EOT Visit: Micro-ITT Analysis Set

Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.

Time frame:
At EOT visit (Within 24 hours after last infusion on Day 14)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Cure at EOT Visit: Micro-ITT Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Percentage of Participants With Clinical Cure at EOT Visit: Micro-ITT Analysis Set79.7 (73.3 to 85.1)80.9 (72.0 to 87.8)
Statistical analysis
  • Aztreonam-avibactam ± Metronidazole vs Meropenem± Colistimethate · Difference in clinical cure: -1.2 · 95% CI -10.7 to 9.4CI for the difference was calculated using the unstratified Miettinen and Nurminen method.
Other pre-specifiedPercentage of Participants With Clinical Cure at EOT Visit: CE Analysis Set

Clinical cure = improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.

Time frame:
At EOT visit (Within 24 hours after last infusion on Day 14)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Cure at EOT Visit: CE Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Percentage of Participants With Clinical Cure at EOT Visit: CE Analysis Set82.2 (76.6 to 86.8)81.9 (73.7 to 88.4)
Statistical analysis
  • Aztreonam-avibactam ± Metronidazole vs Meropenem± Colistimethate · Difference in clinical cure: 0.3 · 95% CI -8.3 to 9.9CI for the difference was calculated using the unstratified Miettinen and Nurminen method.
Other pre-specifiedPercentage of Participants With Clinical Cure at EOT Visit: ME Analysis Set

Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.

Time frame:
At EOT visit (Within 24 hours after last infusion on Day 14)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Cure at EOT Visit: ME Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Percentage of Participants With Clinical Cure at EOT Visit: ME Analysis Set84.6 (78.1 to 89.7)83.5 (74.2 to 90.4)
Statistical analysis
  • Aztreonam-avibactam ± Metronidazole vs Meropenem± Colistimethate · Difference in clinical cure rate: 1.0 · 95% CI -8.5 to 12.0CI for the difference was calculated using the unstratified Miettinen and Nurminen method.
Other pre-specifiedPercentage of Participants With Clinical Cure by Type of Infection at EOT Visit: ITT Analysis Set

Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.

Time frame:
At EOT visit (Within 24 hours after last infusion on Day 14)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Cure by Type of Infection at EOT Visit: ITT Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
cIAI81.7 (76.1 to 86.5)79.8 (71.3 to 86.6)
HAP/VAP59.5 (48.1 to 70.1)55.6 (39.4 to 70.8)
Statistical analysis
  • Aztreonam-avibactam ± Metronidazole vs Meropenem± Colistimethate · Difference in clinical cure rate: 1.9 · 95% CI -6.9 to 11.9CI for the difference was calculated using the unstratified Miettinen and Nurminen method.
  • Aztreonam-avibactam ± Metronidazole vs Meropenem± Colistimethate · Difference in clinical cure rate: 3.9 · 95% CI -15.2 to 23.4CI for the difference was calculated using the unstratified Miettinen and Nurminen method.
Other pre-specifiedPercentage of Participants With Clinical Cure by Type of Infection at EOT Visit: CE Analysis Set

Clinical cure = improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.

Time frame:
At EOT visit (Within 24 hours after last infusion on Day 24)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Cure by Type of Infection at EOT Visit: CE Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
cIAI88.7 (83.2 to 92.8)85.5 (76.8 to 91.8)
HAP/VAP57.8 (43.2 to 71.4)68.2 (47.4 to 84.5)
Statistical analysis
  • Aztreonam-avibactam ± Metronidazole vs Meropenem± Colistimethate · Difference in clinical cure rate: 3.1 · 95% CI -5.2 to 13.2CI for the difference was calculated using the unstratified Miettinen and Nurminen method.
  • Aztreonam-avibactam ± Metronidazole vs Meropenem± Colistimethate · Difference in clinical cure rate: -10.4 · 95% CI -32.6 to 14.9CI for the difference was calculated using the unstratified Miettinen and Nurminen method.
Other pre-specifiedPercentage of Participants With Clinical Cure by Pathogen Resistance Type at EOT Visit: Micro-ITT Analysis Set

Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. Percentage of participants with clinical cure by pathogen resistance type (ATM non-susceptible and Meropenem non-susceptible based on European Committee on Antimicrobial Susceptibility Testing \[EUCAST\] criteria and Clinical and Laboratory Standards Institute \[CLSI\] criteria, Extended spectrum beta-lactamases \[ESBL\]-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.

Time frame:
At EOT visit (Within 24 hours after last infusion on Day 14)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Cure by Pathogen Resistance Type at EOT Visit: Micro-ITT Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
ATM non-susceptible, EUCAST74.575.0
ATM non-susceptible, CLSI68.474.2
Meropenem non-susceptible, EUCAST57.972.7
Meropenem non-susceptible, CLSI58.875.0
ESBL-positive72.075.0
Carbapenemase-positive61.550.0
Serene Carbapenemase57.133.3
Metallo-beta-lactamase-positive57.166.7
Other pre-specifiedPercentage of Participants With Clinical Cure by Pathogen Resistance Type at TOC Visit: Micro-ITT Analysis Set

Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. Percentage of participants with clinical cure by pathogen resistance type (ATM non-susceptible and Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.

Time frame:
At TOC (Day 28)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Cure by Pathogen Resistance Type at TOC Visit: Micro-ITT Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
ATM non-susceptible, EUCAST63.655.6
ATM non-susceptible, CLSI60.561.3
Meropenem non-susceptible,42.145.5
Meropenem non-susceptible, CLSI41.250.0
ESBL-positive68.070.0
Carbapenemase-positive30.833.3
Serene Carbapenemase28.60
Metallo-beta-lactamase-positive28.666.7
Other pre-specifiedPercentage of Participants With Clinical Cure by Pathogen Resistance Type at EOT Visit: ME Analysis Set

Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. Percentage of participants with clinical cure by pathogen resistance type (ATM non-susceptible and Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.

Time frame:
At EOT (Within 24 hours after last infusion on Day 14)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Cure by Pathogen Resistance Type at EOT Visit: ME Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
ATM non-susceptible, EUCAST81.178.6
ATM non-susceptible, CLSI76.776.0
Meropenem non-susceptible, EUCAST69.262.5
Meropenem non-susceptible, CLSI69.262.5
ESBL-positive77.382.4
Carbapenemase-positive80.025.0
Serene Carbapenemase66.733.3
Metallo-beta-lactamase-positive100.00
Other pre-specifiedPercentage of Participants With Clinical Cure by Pathogen Resistance Type at TOC Visit: ME Analysis Set

Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. Percentage of participants with clinical cure by pathogen resistance type (ATM non-susceptible and Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.

Time frame:
At TOC visit (Day 28)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Cure by Pathogen Resistance Type at TOC Visit: ME Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
ATM non-susceptible, EUCAST Criteria70.360.7
ATM non-susceptible, CLSI Criteria66.764.0
Meropenem non-susceptible, EUCAST Criteria46.237.5
Meropenem non-susceptible, CLSI Criteria46.237.5
ESBL-positive72.776.5
Carbapenemase-positive40.00
Serene Carbapenemase33.30
Metallo-beta-lactamase-positive50.00
Other pre-specifiedPercentage of Participants With Favorable Per Participant Microbiological Response at EOT Visit: Micro-ITT Analysis Set

Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure.

Time frame:
At EOT visit (Within 24 hours after last infusion on Day 14)
Reported as:
Number · Percentage of participants
Percentage of Participants With Favorable Per Participant Microbiological Response at EOT Visit: Micro-ITT Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Percentage of Participants With Favorable Per Participant Microbiological Response at EOT Visit: Micro-ITT Analysis Set84.683.9
Other pre-specifiedPercentage of Participants With Favorable Per Participant Microbiological Response at EOT Visit : ME Analysis Set

Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure.

Time frame:
At EOT visit (Within 24 hours after last infusion on Day 14)
Reported as:
Number · Percentage of participants
Percentage of Participants With Favorable Per Participant Microbiological Response at EOT Visit : ME Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Percentage of Participants With Favorable Per Participant Microbiological Response at EOT Visit : ME Analysis Set85.986.1
Other pre-specifiedNumber of Participants With Favorable Microbiological Response Per-Pathogen at EOT Visit: Micro-ITT Analysis Set

Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Only those pathogens are reported which had more than or equal to 10 isolates for either treatment group.

Time frame:
At EOT (Within 24 hours after last infusion on Day 14)
Reported as:
Count of participants · Participants
Number of Participants With Favorable Microbiological Response Per-Pathogen at EOT Visit: Micro-ITT Analysis Set
ParticipantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Escherichia coli9548
Klebsiella pneumoniae1918
Pseudomonas aeruginosa145
Streptococcus anginosus group134
Bacteroides fragilis137
Bacteroides thetaiotaomicron81
Other pre-specifiedNumber of Participants With Favorable Microbiological Response Per-Pathogen at at TOC Visit: Micro-ITT Analysis Set

Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Only those pathogens are reported which had more than or equal to 10 isolates for either treatment group.

Time frame:
At TOC visit (Day 28)
Reported as:
Count of participants · Participants
Number of Participants With Favorable Microbiological Response Per-Pathogen at at TOC Visit: Micro-ITT Analysis Set
ParticipantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Escherichia coli9144
Klebsiella pneumoniae1415
Pseudomonas aeruginosa123
Streptococcus anginosus group124
Bacteroides fragilis147
Bacteroides thetaiotaomicron81
Other pre-specifiedNumber of Participants With Favorable Microbiological Response Per-Pathogen at EOT Visit: ME Analysis Set

Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Only those pathogens are reported which had more than or equal to 10 isolates for either treatment group.

Time frame:
At EOT (Within 24 hours after last infusion on Day 14)
Reported as:
Count of participants · Participants
Number of Participants With Favorable Microbiological Response Per-Pathogen at EOT Visit: ME Analysis Set
ParticipantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Escherichia coli9044
Klebsiella pneumoniae1717
Streptococcus anginosus group133
Bacteroides fragilis136
Bacteroides thetaiotaomicron81
Other pre-specifiedNumber of Participants With Favorable Microbiological Response Per-Pathogen at TOC Visit: ME Analysis Set

Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Only those pathogens are reported which had more than or equal to 10 isolates for either treatment group.

Time frame:
At TOC visit (Day 28)
Reported as:
Count of participants · Participants
Number of Participants With Favorable Microbiological Response Per-Pathogen at TOC Visit: ME Analysis Set
ParticipantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Escherichia coli8640
Klebsiella pneumoniae1314
Streptococcus anginosus group123
Bacteroides fragilis146
Bacteroides thetaiotaomicron81
Other pre-specifiedPercentage of Participants With Favorable Per-Participant Microbiological Response by Pathogen Resistance Type at EOT Visit: Micro-ITT Analysis Set

Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable microbiological response by pathogen resistance type (ATM non-susceptible and Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.

Time frame:
At EOT (Within 24 hours after last infusion on Day 14)
Reported as:
Number · Percentage of participants
Percentage of Participants With Favorable Per-Participant Microbiological Response by Pathogen Resistance Type at EOT Visit: Micro-ITT Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
ATM non-susceptible: CLSI68.878.6
ATM non-susceptible : EUCAST76.280.6
Meropenem non-susceptible : CLSI57.166.7
Meropenem non-susceptible : EUCAST57.166.7
ESBL-positive78.384.2
Carbapenamase-positive50.025.0
Serene Carbapenamase-positive33.333.3
Metallo-beta-lactamase-positive75.00.0
Other pre-specifiedPercentage of Participants With Favorable Per-Participant Microbiological Response by Pathogen Resistance Type at TOC Visit: Micro-ITT Analysis Set

Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable microbiological response by pathogen resistance type (ATM non-susceptible and Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.

Time frame:
At TOC visit (Day 28)
Reported as:
Number · Percentage of participants
Percentage of Participants With Favorable Per-Participant Microbiological Response by Pathogen Resistance Type at TOC Visit: Micro-ITT Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
ATM non-susceptible: CLSI59.459.3
ATM non-susceptible: EUCAST66.760.0
Meropenem non-susceptible: CLSI28.625.0
Meropenem non-susceptible : EUCAST28.625.0
ESBL-positive73.973.7
Carbapenamase-positive20.00.0
Serene Carbapenamase-positive16.70.0
Metallo-beta-lactamase-positive25.00.0
Other pre-specifiedPercentage of Participants With Favorable Per-Participant Microbiological Response by Pathogen Resistance Type at EOT Visit: ME Analysis Set

Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable microbiological response by pathogen resistance type (ATM non-susceptible, Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.

Time frame:
At EOT (Within 24 hours after last infusion on Day 14)
Reported as:
Number · Percentage of participants
Percentage of Participants With Favorable Per-Participant Microbiological Response by Pathogen Resistance Type at EOT Visit: ME Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
ATM non-susceptible: CLSI70.080.0
ATM non-susceptible: EUCAST75.082.1
Meropenem non-susceptible: CLSI53.862.5
Meropenem non-susceptible: EUCAST53.862.5
ESBL-positive77.388.2
Carbapenamase-positive44.425.0
Serene Carbapenamase-positive33.333.3
Metallo-beta-lactamase-positive66.70.0
Other pre-specifiedPercentage of Participants With Favorable Per-Participant Microbiological Response by Pathogen Resistance Type at TOC Visit: ME Analysis Set

Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable microbiological response by pathogen resistance type (ATM non-susceptible, Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.

Time frame:
At TOC visit (Day 28)
Reported as:
Number · Percentage of participants
Percentage of Participants With Favorable Per-Participant Microbiological Response by Pathogen Resistance Type at TOC Visit: ME Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
ATM non-susceptible: CLSI60.060.0
ATM non-susceptible: EUCAST66.760.7
Meropenem non-susceptible: CLSI30.825.0
Meropenem non-susceptible: EUCAST30.825.0
ESBL-positive72.776.5
Carbapenamase-positive22.20.0
Serene Carbapenamase-positive16.70.0
Metallo-beta-lactamase-positive33.30.0
Other pre-specifiedPercentage of Participants With Favorable Per-Pathogen Microbiological Response by Pathogen Resistance Type at EOT Visit: Micro-ITT Analysis Set

Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable per-pathogen microbiological response by pathogen resistance type (ATM non-susceptible, Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.

Time frame:
At EOT (Within 24 hours after last infusion on Day 14)
Reported as:
Number · Percentage of participants
Percentage of Participants With Favorable Per-Pathogen Microbiological Response by Pathogen Resistance Type at EOT Visit: Micro-ITT Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
ATM non-susceptible: CLSI68.377.4
ATM non-susceptible: EUCAST73.378.4
Meropenem non-susceptible: CLSI60.075.0
Meropenem non-susceptible : EUCAST59.172.7
ESBL-positive72.080.0
Carbapenemase-positive61.550.0
Serine-carbapenemase-positive42.933.3
Metallo-beta-lactamase-positive71.466.7
Other pre-specifiedPercentage of Participants With Favorable Per-Pathogen Microbiological Response by Pathogen Resistance Type at TOC Visit: Micro-ITT Analysis Set

Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable per-pathogen microbiological response by pathogen resistance type (ATM non-susceptible, Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.

Time frame:
At TOC visit (Day 28)
Reported as:
Number · Percentage of participants
Percentage of Participants With Favorable Per-Pathogen Microbiological Response by Pathogen Resistance Type at TOC Visit: Micro-ITT Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
ATM non-susceptible: CLSI58.558.1
ATM non-susceptible: EUCAST63.356.8
Meropenem non-susceptible: CLSI30.041.7
Meropenem non-susceptible: EUCAST31.836.4
ESBL-positive72.070.0
Carbapenemase-positive23.133.3
Serine-carbapenemase-positive14.30.0
Metallo-beta-lactamase-positive28.666.7
Other pre-specifiedPercentage of Participants With Favorable Per-Pathogen Microbiological Response by Pathogen Resistance Type at EOT Visit: ME Analysis Set

Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable per-pathogen microbiological response by pathogen resistance type (ATM non-susceptible, Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.

Time frame:
At EOT (Within 24 hours after last infusion on Day 14)
Reported as:
Number · Percentage of participants
Percentage of Participants With Favorable Per-Pathogen Microbiological Response by Pathogen Resistance Type at EOT Visit: ME Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
ATM non-susceptible: CLSI75.880.0
ATM non-susceptible: EUCAST78.682.8
Meropenem non-susceptible: CLSI62.562.5
Meropenem non-susceptible: EUCAST62.562.5
ESBL-positive77.388.2
Carbapenemase-positive70.025.0
Serine-carbapenemase-positive50.33.3
Metallo-beta-lactamase-positive100.00.0
Other pre-specifiedPercentage of Participants With Favorable Per-Pathogen Microbiological Response by Pathogen Resistance Type at TOC Visit: ME Analysis Set

Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable per-pathogen microbiological response by pathogen resistance type (ATM non-susceptible, Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.

Time frame:
At TOC visit (Day 28)
Reported as:
Number · Percentage of participants
Percentage of Participants With Favorable Per-Pathogen Microbiological Response by Pathogen Resistance Type at TOC Visit: ME Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
ATM non-susceptible: CLSI63.660.0
ATM non-susceptible: EUCAST66.762.1
Meropenem non-susceptible: CLSI31.325.0
Meropenem non-susceptible : EUCAST31.325.0
ESBL-positive:77.376.5
Carbapenemase-positive:30.00.0
Serine-carbapenemase-positive16.70.0
Metallo-beta-lactamase-positive:50.00.0
Other pre-specifiedNumber of Participants According to Total Score for the Composite Endpoint of Symptom-Based Objective Clinical Measures: ITT Analysis Set
Time frame:
Up to Day 28

No measurements were reported for this outcome.

Other pre-specifiedNumber of Participants According to Total Score for the Composite Endpoint of Symptom-Based Objective Clinical Measures: CE Analysis Set

CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.

Time frame:
Up to Day 28

No measurements were reported for this outcome.

Other pre-specifiedPercentage of Participants Who Died on or Before 14 Days From Randomization: ITT Analysis Set

Percentage of participants who died on or before 14 days from randomization is reported in this outcome measure.

Time frame:
From randomization up to 14 days
Reported as:
Number · Percentage of participants
Percentage of Participants Who Died on or Before 14 Days From Randomization: ITT Analysis Set
Percentage of participantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Percentage of Participants Who Died on or Before 14 Days From Randomization: ITT Analysis Set2.83.6
Other pre-specifiedTotal Length of Hospital Stay up to TOC Visit: ITT Analysis Set

The total length of hospital stay was defined as the total number of calendar days on which the participant was in the hospital from the date of randomization up to and including the specified time point of TOC.

Time frame:
From randomization up to Day 28
Reported as:
Mean · Days
Total Length of Hospital Stay up to TOC Visit: ITT Analysis Set
DaysAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Total Length of Hospital Stay up to TOC Visit: ITT Analysis Set13.6 ± 9.4212.9 ± 8.05
Other pre-specifiedTotal Length of Hospital Stay up to TOC Visit: CE Analysis Set

The total length of hospital stay was defined as the total number of calendar days on which the participant was in the hospital from the date of randomization up to and including the specified time point of TOC. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.

Time frame:
From randomization up to Day 28
Reported as:
Mean · Days
Total Length of Hospital Stay up to TOC Visit: CE Analysis Set
DaysAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Total Length of Hospital Stay up to TOC Visit: CE Analysis Set13.0 ± 8.5512.3 ± 7.29
Other pre-specifiedDuration of Study Treatment

The duration of therapy in calendar days were calculated as follows: Date of last dose of study drug - date of first dose of study drug +1.

Time frame:
From first dose of study treatment until last dose of treatment (Up to 14 days)
Reported as:
Mean · Days
Duration of Study Treatment
DaysAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Duration of Study Treatment8.5 ± 3.528.9 ± 3.17
Other pre-specifiedLength of Intensive Care Unit (ICU) Stay: ITT Analysis Set

The total length of ICU stay was defined as the total number of calendar days on which the participant was in ICU for the period from date of randomization until the TOC visit.

Time frame:
From randomization until TOC visit (Up to Day 28)
Reported as:
Mean · Days
Length of Intensive Care Unit (ICU) Stay: ITT Analysis Set
DaysAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Length of Intensive Care Unit (ICU) Stay: ITT Analysis Set11.6 ± 9.1012.5 ± 9.45
Other pre-specifiedLength of Intensive Care Unit (ICU) Stay: CE Analysis Set

The total length of ICU stay was defined as the total number of calendar days on which the participant was in ICU for the period from date of randomization until the TOC visit. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.

Time frame:
From randomization until TOC visit (Up to Day 28)
Reported as:
Mean · Days
Length of Intensive Care Unit (ICU) Stay: CE Analysis Set
DaysAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Length of Intensive Care Unit (ICU) Stay: CE Analysis Set12.1 ± 9.2312.4 ± 9.38
Other pre-specifiedNumber of Participants Admitted to the ICU: ITT Analysis Set

Number of participants admitted to the ICU up to TOC were reported in this outcome measure.

Time frame:
From randomization until TOC visit (Up to Day 28)
Reported as:
Count of participants · Participants
Number of Participants Admitted to the ICU: ITT Analysis Set
ParticipantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Number of Participants Admitted to the ICU: ITT Analysis Set8039
Other pre-specifiedNumber of Participants Admitted to the ICU: CE Analysis Set

The number of participants admitted to the ICU were reported in this outcome measure. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.

Time frame:
From randomization until TOC visit (Up to Day 28)
Reported as:
Count of participants · Participants
Number of Participants Admitted to the ICU: CE Analysis Set
ParticipantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Number of Participants Admitted to the ICU: CE Analysis Set5424
Other pre-specifiedNumber of Participants With Mechanical Ventilation: ITT Analysis Set

Number of participants with mechanical ventilation were reported in this outcome measure.

Time frame:
From randomization until TOC visit (Up to Day 28)
Reported as:
Count of participants · Participants
Number of Participants With Mechanical Ventilation: ITT Analysis Set
ParticipantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Number of Participants With Mechanical Ventilation: ITT Analysis Set4321
Other pre-specifiedNumber of Participants With Mechanical Ventilation: CE Analysis Set

Number of participants with mechanical ventilation were reported in this outcome measure. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.

Time frame:
From randomization until TOC visit (Up to Day 28)
Reported as:
Count of participants · Participants
Number of Participants With Mechanical Ventilation: CE Analysis Set
ParticipantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Number of Participants With Mechanical Ventilation: CE Analysis Set2413
Other pre-specifiedDuration of Mechanical Ventilation in HAP/VAP Participants: ITT Analysis Set

Duration of mechanical ventilation was defined as the total number of calendar days on which the participant required mechanical ventilation from the date of randomization up to TOC.

Time frame:
From randomization until TOC visit (Up to Day 28)
Reported as:
Mean · Days
Duration of Mechanical Ventilation in HAP/VAP Participants: ITT Analysis Set
DaysAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Duration of Mechanical Ventilation in HAP/VAP Participants: ITT Analysis Set14.2 ± 9.9416.7 ± 11.16
Other pre-specifiedDuration of Mechanical Ventilation in HAP/VAP Participants: CE Analysis Set

Duration of mechanical ventilation was defined as the total number of calendar days on which the participant required mechanical ventilation from the date of randomization up to TOC. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.

Time frame:
From randomization until TOC visit (Up to Day 28)
Reported as:
Mean · Days
Duration of Mechanical Ventilation in HAP/VAP Participants: CE Analysis Set
DaysAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Duration of Mechanical Ventilation in HAP/VAP Participants: CE Analysis Set17.4 ± 8.9919.5 ± 11.16
Other pre-specifiedNumber of Participants With Unplanned Surgical Interventions in Complicated Intra-abdominal Infections (cIAI) Participants: ITT Analysis Set

Unplanned surgical interventions was defined as those occurring after the initial qualifying surgical intervention and prior to the TOC visit. Number of cIAI participants with unplanned surgical intervention according to clinical response categories of cure and failure is reported in this outcome measure.

Time frame:
From randomization until TOC visit (Up to Day 28)
Reported as:
Count of participants · Participants
Number of Participants With Unplanned Surgical Interventions in Complicated Intra-abdominal Infections (cIAI) Participants: ITT Analysis Set
ParticipantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Cure11
Failure510
Other pre-specifiedNumber of Participants With Unplanned Surgical Interventions in cIAI Participants: CE Analysis Set

Unplanned surgical interventions was defined as those occurring after the initial qualifying surgical intervention and prior to the TOC visit. Number of cIAI participants with unplanned surgical intervention according to clinical response categories of cure and failure is reported in this outcome measure.

Time frame:
From randomization until TOC visit (Up to Day 28)
Reported as:
Count of participants · Participants
Number of Participants With Unplanned Surgical Interventions in cIAI Participants: CE Analysis Set
ParticipantsAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Cure11
Failure59

Adverse events

Collected over All-cause mortality: From signing of informed consent until end of late follow up visit (Day 45); non-SAEs and SAEs: From start of study treatment until end of late follow-up visit (Up to Day 45).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aztreonam-avibactam ± Metronidazole20/282 (7.1%)53/275 (19.3%)113/275 (41.1%)
Meropenem± Colistimethate11/140 (7.9%)25/137 (18.2%)45/137 (32.8%)
Most frequent serious events
Showing 10 of 77
Most frequent serious events
EventAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
Septic shockInfections and infestations2/2753/137
Cardiac arrestCardiac disorders2/2752/137
Intra-abdominal fluid collectionGastrointestinal disorders0/2752/137
Abdominal abscessInfections and infestations4/2752/137
SepsisInfections and infestations2/2752/137
Respiratory failureRespiratory, thoracic and mediastinal disorders3/2752/137
PneumoniaInfections and infestations4/2751/137
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/2750/137
COVID-19Infections and infestations3/2750/137
Disseminated intravascular coagulationBlood and lymphatic system disorders0/2751/137
Most frequent other events
Showing 10 of 21
Most frequent other events
EventAztreonam-avibactam ± MetronidazoleMeropenem± Colistimethate
AnaemiaBlood and lymphatic system disorders20/2757/137
Alanine aminotransferase increasedInvestigations18/2757/137
DiarrhoeaGastrointestinal disorders16/2755/137
HypokalaemiaMetabolism and nutrition disorders16/2754/137
Aspartate aminotransferase increasedInvestigations15/2755/137
PyrexiaGeneral disorders14/2755/137
Hepatic function abnormalHepatobiliary disorders11/2753/137
NauseaGastrointestinal disorders10/2753/137
VomitingGastrointestinal disorders10/2752/137
Abdominal painGastrointestinal disorders6/2754/137

Baseline characteristics

The Intent to Treat (ITT) analysis set included all randomized participants regardless of receipt of study drug. Participants were analyzed according to the treatment to which they were randomized.

Age, Continuous
Age, Continuous(Years)Aztreonam-avibactam ± MetronidazoleMeropenem± ColistimethateTotal
Mean55.2 ± 17.8454.0 ± 16.3054.8 ± 17.33
Sex: Female, Male
Sex: Female, Male(Participants)Aztreonam-avibactam ± MetronidazoleMeropenem± ColistimethateTotal
Female9639135
Male186101287
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Aztreonam-avibactam ± MetronidazoleMeropenem± ColistimethateTotal
Hispanic or Latino582179
Not Hispanic or Latino213113326
Unknown or Not Reported11617
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Aztreonam-avibactam ± MetronidazoleMeropenem± ColistimethateTotal
White16464228
Black or African American112
Asian10769176
American Indian or Alaska Native729
Mixed213
Other011
Not reported123
08

Study locations

157 sites
  • Banner University Medical Center - Tucson
    Tucson, Arizona 85719, United States
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
    Torrance, California 90502, United States
  • Harbor-UCLA Medical Center
    Torrance, California 90509, United States
  • Southern Illinois University School of Medicine
    Springfield, Illinois 62702, United States
  • Memorial Medical Center
    Springfield, Illinois 62781, United States
  • Sanatorio Britanico
    Rosario, Santa FE 2000, Argentina
  • Sanatorio Servicios Medicos SM
    Santo Tome, Santa FE S3016, Argentina
  • Hospital San Roque
    Córdoba, 5000, Argentina
  • University Hospital Alexandrovska, Clinic of Anesthesiology and Intensive Care
    Sofia, 1431, Bulgaria
  • University Hospital Queen Joanna ISUL, Clinic of Surgery
    Sofia, 1527, Bulgaria
  • University Multiprofile Hospital for Active Treatment ''Prof.Dr Stoyan Kirkovich''AD
    Stara Zagora, 6003, Bulgaria
  • Peking University Third Hospital
    Beijing, Beijing 100191, China
  • Zhangzhou Municipal Hospital of Fujian Province
    Zhangzhou, Fujian 363000, China
  • ZhuJiang Hospital of Southern Medical University
    Guangzhou, Guangdong 510280, China
  • The First Affiliated Hospital of Shantou University Medical College
    Shantou, Guangdong 515041, China
  • The Second People's Hospital of Shenzhen
    Shenzhen, Guangdong 518035, China
  • Nanning First People's Hospital
    Nanning, Guangxi Zhuang Autonomous Region 530022, China
  • Affiliated Hospital of Guilin Medical University
    Guilin, Guangxi 541001, China
  • Changsha Third Hospital
    Changsha, Hunan 410000, China
  • Hunan Province People's Hospital
    Changsha, Hunan 410005, China
  • Baotou Central Hospital
    Baotou, Inner Mongolia Autonomous Region 014000, China
  • Jiangyin People's Hospital
    Jiangyin, Jiangsu 214400, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu 212001, China
  • Huashan Hospital, Fudan University
    Shanghai, Shanghai 200040, China
  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai 200433, China
  • The First people's Hospital of Kunming
    Kunming, Yunnan 650034, China
  • The First Affiliated Hospital of College of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310003, China
  • Taizhou Hospital of Zhejiang Province
    Linhai, Zhejiang 317000, China
  • Lishui People's Hospital
    Lishui, Zhejiang 323000, China
  • Quzhou People's Hospital
    Quzhou, Zhejiang 324000, China
  • Peking University People's Hospital
    Beijing, 100044, China
  • Jiangyin People's Hospital
    Jiangyin, 214400, China
  • Tianjin Union Medical Center
    Tianjin, 300000, China
  • Klinicka bolnica Merkur
    Zagreb, GRAD Zagreb 10000, Croatia
  • Klinicki bolnicki centar Rijeka
    Rijeka, Primorsko-goranska Zupanija 51000, Croatia
  • University Hospital Centre Osijek
    Osijek, 31000, Croatia
  • General Hospital "Dr. Josip Bencevic" Slavonski Brod
    Slavonski Brod, 35000, Croatia
  • Clinical Hospital Dubrava
    Zagreb, 10000, Croatia
  • Fakultni nemocnice Brno
    Brno, 625 00, Czechia
  • Krajska zdravotni, a.s. - Nemocnice Decin, o.z.
    Decin, 40599, Czechia
  • Lekarna Nemocnice Decin, Krajska zdravotni, a.s.- Nemocnice Decin, o.z.
    Decin, 40599, Czechia
  • Public Hospital Kolin, a.s.
    Kolin III, 280 02, Czechia
  • Nemocnice Kyjov, prispevkova organizace
    Kyjov, 697 01, Czechia
  • Fakultni nemocnice Kralovske Vinohrady
    Praha 10, 100 34, Czechia
  • General Hospital of Athens "Evangelismos"
    Athens, 10676, Greece
  • General and Chest Diseases Hospital "Sotiria"
    Athens, 11527, Greece
  • General Hospital of Athens "Laiko"
    Athens, 11527, Greece
  • University General Hospital "ATTIKON"
    Athens, 12462, Greece
  • University General Hospital of Heraklion
    Heraklion, Crete, 71110, Greece
  • University General Hospital of Larissa
    Larissa, 41110, Greece
  • Koutlimbaneio and Triantafylleio General Hospital of Larissa
    Larissa, 41221, Greece
  • King George Hospital
    Visakhapatnam, Andhra Pradesh 530002, India
  • Victoria Hospital, Bangalore Medical College and Research Institute
    Bangalore, Karnataka 560002, India
  • M S Ramaiah Medical College and Hospitals
    Bangalore, Karnataka 560054, India
  • Kasturba Medical College and Hospital
    Manipal, Karnataka 576104, India
  • JSS Hospital
    Mysuru, Karnataka 570004, India
  • Amrita Institute of Medical Sciences & Research Centre
    Kochi, Kerala 682041, India
  • Government Medical College, Kozhikode
    Kozhikode, Kerala 673008, India
  • Deenanath Mangeshkar Hospital And Research Centre
    Pune, Maharashtra 411004, India
  • Sahyadri Super Speciality Hospital
    Pune, Maharashtra 411004, India
  • Sahyadri Super Specialty Hospital
    Pune, Maharashtra 411004, India
  • S.R. Kalla Memorial Gastro & General Hospital
    Jaipur, Rajasthan 302001, India
  • Apollo Hospitals
    Chennai, Tamil NADU 600006, India
  • King George's Medical University
    Lucknow, Uttar Pradesh 226003, India
  • Dayanand Medical College and Hospital
    Ludhiana, 141001, India
  • Sahyadri Clinical Research & Development Center
    Pune, 411004, India
  • Sahyadri Specialty Hospital
    Pune, India
  • Assuta Ashdod University Hospital
    Ashdod, 7747629, Israel
  • Rambam Health Care Campus
    Haifa, 3109601, Israel
  • Hadassah Medical Organization, Hadassah Medical Center, Ein-Karem
    Jerusalem, 9112001, Israel
  • Rabin Medical Center, Beilinson Hospital
    Petah Tikva, 4941492, Israel
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 6423906, Israel
  • The Chaim Sheba Medical Center
    Tel-Hashomer, 5265601, Israel
  • Shamir Medical Center, Infectious Diseases Unit
    Zerifin, 7030000, Israel
  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
    Milano, Milan 20122, Italy
  • Azienda Ospedaliero-Universitaria Ospedali Riuniti
    Foggia, 71122, Italy
  • Azienda Ospedaliero Universitaria di Modena
    Modena, 41124, Italy
  • Farmacia Ospedaliera - Direzione Assistenza Farmaceutica
    Modena, 41124, Italy
  • SC di Radiologia - Azienda Ospedaliera Universitaria di Modena
    Modena, 41124, Italy
  • Azienda Ospedaliero-Universitaria Pisana Ospedale Cisanello
    Pisa, 56100, Italy
  • UO Radiognastostica 2 Azienda Ospedaliero-Universitaria Pisana Ospedale Cisanello
    Pisa, 56100, Italy
  • UO Farmaceutica Azienda Ospedaliero-Universitaria Pisana
    Pisa, 56126, Italy
  • Azienda Sanitaria Universitaria Friuli Centrale (ASU FC), Presidio Ospedaliero Universitario Santa
    Udine, 33100, Italy
  • Gachon University Gil Medical Center - Infectious Disease
    Incheon, Incheon Gwang'yeogsiv 21565, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • The Catholic University of Korea, Eunpyeong St. Mary's Hospital
    Seoul, 03312, Korea, Republic of
  • Hallym University Kangnam Sacred Heart Hospital
    Seoul, 07441, Korea, Republic of
  • Hospital Seberang Jaya
    Seberang Jaya, Pulau Pinang 13700, Malaysia
  • Hospital Sultanah Nur Zahirah
    Kuala Terengganu, Terengganu 20400, Malaysia
  • University Malaya Medical Centre
    Kuala Lumpur, 59100, Malaysia
  • Hospital Civil Fray Antonio Alcalde
    Guadalajara, Jalisco 44280, Mexico
  • Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
    Monterrey, Nuevo LEON 64460, Mexico
  • De La Salle Medical and Health Sciences Institute
    City Of Dasmarinas, Cavite 4114, Philippines
  • Baguio General Hospital and Medical Center
    Baguio City, 2600, Philippines
  • Davao Doctors Hospital
    Davao City, 8000, Philippines
  • St. Paul's Hospital of Iloilo, Inc.
    Iloilo City, 5000, Philippines
  • West Visayas State University Medical Center
    Iloilo City, 5000, Philippines
  • Makati Medical Center
    Makati City, 1229, Philippines
  • Philippine General Hospital, Central Intensive Care Unit
    Manila, 1000, Philippines
  • Asian Hospital and Medical Center
    Muntinlupa City, 1780, Philippines

Showing the first 100 of 157 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Feb 2023, 58 months.

Results were first posted in May 2024, 1 year 2 months after primary completion.

Of 16 phase 3 interventional studies under Pneumonia, Ventilator-Associated, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 59. This study's 58 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2017
First posted
Nov 1, 2017
StartActual
Apr 5, 2018
Primary completionActual
Feb 23, 2023
CompletionActual
Feb 23, 2023
Results first posted
May 7, 2024
Last update
Dec 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03329092
Lead sponsor
Pfizer
Collaborators
Innovative Medicines Initiative, Biomedical Advanced Research and Development Authority
Responsible party
Sponsor
First posted
Nov 1, 2017
Start date
Apr 5, 2018
Primary completion
Feb 23, 2023
Completion
Feb 23, 2023
Results posted
May 7, 2024
Last update
Dec 10, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion